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Introduction: The American Thyroid Association appointed a Task Force of experts to revise the original
Medullary Thyroid Carcinoma: Management Guidelines of the American Thyroid Association.
Methods: The Task Force identified relevant articles using a systematic PubMed search, supplemented with
additional published materials, and then created evidence-based recommendations, which were set in categories
using criteria adapted from the United States Preventive Services Task Force Agency for Healthcare Research
and Quality. The original guidelines provided abundant source material and an excellent organizational
structure that served as the basis for the current revised document.
Results: The revised guidelines are focused primarily on the diagnosis and treatment of patients with sporadic
medullary thyroid carcinoma (MTC) and hereditary MTC.
Conclusions: The Task Force developed 67 evidence-based recommendations to assist clinicians in the care of
patients with MTC. The Task Force considers the recommendations to represent current, rational, and optimal
medical practice.
OVERVIEW
According to current Surveillance, Epidemiology, andEnd Results (SEER) data, medullary thyroid carcinoma
(MTC) accounts for 1%–2% of thyroid cancers in the United
States, a much lower range than frequently cited (3%–5%),
primarily due to the marked increase in the relative incidence
of papillary thyroid carcinoma (PTC) over the last three de-
cades (1). Advances in the basic research and clinical in-
vestigation of MTC reported in specialty publications of
endocrinology, genetics, nuclear medicine, oncology, pathol-
ogy, pediatrics, radiology, and surgery make it challenging for
clinicians to remain current on new developments. Several
academic organizations have published guidelines for the
management of patients with MTC (2–4). In 2007 the
American Thyroid Association (ATA) assembled a group of
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expert clinicians and basic scientists to evaluate published pa-
pers and to recommend evidence-based guidelines for the di-
agnosis andmanagement of patients withMTC. The guidelines
were published in 2009 (5). The current document is the first
revision of the original guidelines, and it is hoped that it will
assist clinicians of all specialties in the management of patients
with MTC. It is not the intent of the guidelines to replace the
individual physician’s decision-making or the wishes of the
patient or the patient’s family.
Methods
Presentation of results and recommendations
Table 1 lists the topics addressed by the Guidelines Task
Force (Task Force). Specific recommendations (R) regarding
patient management are numbered in the body of the guidelines.
The location key can be used if viewing the guidelines in a file or
web page. Each location key is unique and can be copied into the
Find or Search function to navigate to the section of interest.
Table 2 lists the abbreviations used throughout the document.
Administration
The ATA Board of Directors selected a Task Force
Chairman based on clinical experience with MTC and the
absence of dogmatically held views in areas of recognized
controversy. Task Force members were selected based on
clinical and research expertise and included international
scientists from the fields of endocrinology, ethics, genetics,
molecular biology, medical oncology, pathology, pediatrics,
nuclear medicine, radiation oncology, and surgery. All Task
Force members disclosed potential conflicts of interest.
Teams of Task Force members reviewed and revised
specific sections of the original document. The teams’ rec-
ommendations were the basis for a preliminary draft of the
revised guidelines. After subsequent revisions and critical
reviews of a series of drafts the Task Force developed a final
document. The consensus was most often unanimous; how-
ever, on some issues there were disparate views among Task
Force members, which are noted in the document. The ATA
Board of Directors approved the final document, and it was
subsequently endorsed by the American Academy of Pedia-
trics; American Association of Clinical Endocrinologists;
American Association of Endocrine Surgeons; American
Head & Neck Society; American Society of Pediatric He-
matology/Oncology; Australian and New Zealand Endocrine
Surgeons; British Association of Head and Neck Oncolo-
gists; British Nuclear Medicine Society; European Thyroid
Association; International Association of Endocrine Surgeons;
International Federation of Head and Neck Oncologic Socie-
ties; Italian Endocrine Society; Korean Society of Thyroid-
Head and Neck Surgery; Latin American Thyroid Society;
Pediatric Endocrine Society; and The Endocrine Society.
Literature review and evidence-based medicine
The Task Force identified relevant articles by searching
MEDLINE/PubMed from January 1980 to April 2014 using
the following search terms: calcitonin, medullary carcinoma,
medullary thyroid cancer, multiple endocrine neoplasia,
multiple endocrine neoplasia type 2A, multiple endocrine
neoplasia type 2B, RET, and thyroid cancer. Task Force
members also provided additional relevant articles, book
chapters, and other materials. The Task Force members
graded recommendations using criteria adapted from the
United States Preventive Services Task Force, Agency for
Healthcare Research and Quality (Table 3) as were used in
the previous MTC guidelines (5).
Table 1. Organization of Revised American Thyroid Association Guidelines
for the Management of Medullary Thyroid Carcinoma
Section/subsection R number
Location
(page)
[A] Background 569
[B] Etiology of sporadic and hereditary MTC 1 569–572
[C] Clinical characteristics and relationship between genotype and phenotype in patients
with sporadic MTC and patients with hereditary MTC
572
[C-1] Sporadic MTC 572
[C-2] Hereditary MTC 2 572
[C-2-1] MEN2A 572
[C-2-1-1] Classical MEN2A 572
[C-2-1-2] MEN2A and CLA 573
[C-2-1-3] MEN2A and HD 573
[C-2-1-4] FMTC 573
[C-2-2] MEN2B 573
[D] Direct DNA analysis to detect mutations in the RET protooncogene 3–5 574
[D-1] Direct DNA analysis to detect RET germline mutations in patients with apparent
sporadic MTC
6–9 574–575
[E] Ethical considerations for genetic screening 575
[E-1] Adults 10 575
[E-2] The pediatric population 11 575
[E-3] Reproductive options of RET mutation carriers 575–576
[E-4] Ethical considerations for preconception and prenatal counseling 12 576
(continued)
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[A] BACKGROUND
Over 100 years ago Jacquet described a thyroid tumor with
amyloid; however, it was not until 1959 that Hazard and
associates provided a definitive histological description of
medullary thyroid carcinoma (MTC) and so named it (6,7).
Williams discovered that MTC originated from the neural
crest derived parafollicular C-cells of the thyroid gland (8).
Tashjian and colleagues discovered that the C-cells secrete
the polypeptide calcitonin (Ctn), and they and subsequently
others showed that intravenously administered calcium,
pentagastrin, or both together, are potent Ctn secretagogues
(9,10). Shortly after the discovery that MTC represents a
unique thyroid cancer, it was recognized that the tumor oc-
curred either sporadically or in a hereditary form as a com-
ponent of the type 2 multiple endocrine neoplasia (MEN)
syndromes, MEN2A and MEN2B, and the related syndrome,
familial MTC (FMTC).
[B] ETIOLOGY OF SPORADIC AND HEREDITARY MTC
The RET protooncogene, located on chromosome 10q11.2,
encodes a single-pass transmembrane receptor of the tyrosine
kinase family. RET is expressed in cells derived from the
Table 1. (Continued)
Section/subsection R number
Location
(page)
[F] Secretory products of MTC 576
[F-1] Calcitonin 13, 14 576–577
[F-2] Carcinoembryonic antigen 15 577
[G] Morphological examination of an excisional biopsy or the thyroidectomy specimen 16–18 578
[H] The diagnosis of MTC in patients presenting with a thyroid nodule 578
[H-1] Fine-needle aspiration biopsy 19 578–580
[H-2] Measurement of the serum Ctn level in patients with nodular thyroid disease 20 580
[I] Management of patients with a thyroid nodule and histological documentation of MTC 580
[I-1] Preoperative imaging studies 21–23 580–581
[I-2] The initial surgical treatment of patients with MTC 24–26 581–582
[J] Results of thyroidectomy in patients with MTC 582–583
[K] Management of patients with locally advanced or metastatic MTC 27 583
[L] Management of patients following an incomplete thyroidectomy and lymph node dissection 28, 29 583
[M] Management of normal parathyroid glands resected or devascularized during surgery 30 583–584
[N] Hormone replacement following thyroidectomy 31, 32 584
[O] Prophylactic thyroidectomy in children with hereditary MTC 584–585
[O-1] Prophylactic thyroidectomy for children with MEN2A 585–586
[O-2] Prophylactic thyroidectomy for children with MEN2B 33–36 586–587
[P] Management of PHEO in patients with MEN2A and MEN2B 37–41 587–588
[Q] Management of HPTH in patients with MEN2A 42–44 588
[R] Evaluation of patients following thyroidectomy 45–48 588–590
[R-1] Measurement of doubling times of serum Ctn and CEA to determine rate
of progression of MTC
49 590–591
[S] Treatment of patients with regional metastatic MTC 591
[S-1] Neck exploration 50 591
[S-2] Role of postoperative radioiodine ablation 51 591
[S-3] Adjunctive EBRT to the neck 52 591–592
[T] Evaluation of patients with distant metastases 592
[T-1] Role of open or laparoscopic evaluation of the liver and selective venous
catheterization with measurement of hepatic and peripheral vein stimulated Ctn levels
53, 54 592
[U] Diagnosis and treatment of patients with clinically evident metastatic disease 592
[U-1] Brain metastases 55 592–593
[U-2] Bone metastases 56–58 593
[U-3] Lung and mediastinal metastases 59 593
[U-4] Hepatic metastases 60 593
[U-5] Cutaneous metastases 61 593–594
[U-6] Palliation of patients with advanced MTC 62 594
[V] Systemic therapy 63, 64 594
[V-1] The basis for targeted therapy with TKIs 594
[V-1-1] Clinical trials of vandetanib in patients with advanced MTC 594–595
[V-1-2] Clinical trials of cabozantinib in patients with advanced MTC 65 595
[W] Treatment of patients with hormonally active metastases 595
[W-1] Diarrhea 66 595–596
[W-2] Ectopic Cushing’s syndrome 67 596
REVISED ATA MANAGEMENT GUIDELINES FOR MTC 569
neural crest, the branchial arches, and the urogenital system
(11,12). Takahashi and associates discovered the RET (RE-
arranged during Transfection) oncogene in 1985 (13). Within
less than a decade following this observation it was found that
virtually all patients withMEN2A, MEN2B, and FMTC have
RET germline mutations and approximately 50% of sporadic
MTCs have somatic RET mutations (14–19). Investigators
recently discovered that 18%–80% of sporadicMTCs lacking
somaticRETmutations have somaticmutations ofHRAS,KRAS,
or rarely NRAS (20–22). Subsequent exomic sequencing studies
ofMTCs detected no additional common geneticmutations (23).
The somaticRET codonM918Tmutation in sporadicMTC
appears to portend an aggressive clinical course and a poor
prognosis (24,25). In a recent study of 160 patients with
sporadic MTC the prevalence of somatic RET codon M918T
mutations varied depending on tumor size: < 1 cm, 6 (11.3%)
of 53 patients; 1–2 cm, 8 (11.8%) of 68 patients; 2–3 cm, 7
(31.8%) of 22 patients; and > 3 cm, 10 (58.8%) of 17 patients
(26). These data raise the question of whether RET acts alone
as the initiator of oncogenesis in sporadicMTC or is activated
later as a driver of tumor growth, with other genes playing a
significant role in MTC onset. An alternate explanation for
these findings is that M918T mutated tumors have a high
growth rate and are more likely to be diagnosed when they are
larger. Also, an important technical aspect of the study was
that the sensitivity of the mutation calling was only 30%.
Furthermore, the low prevalence of the M918T mutation in
microcarcinomas may represent a different entity such as
carcinoma in situ; precisely because it is not driven by RET.
RET is a remarkable oncogene that is not only central to the
development of sporadic and hereditary MTC but to other
malignant and nonmalignant diseases as well. Chromosomal
translocations activating RET occur in 20%–30% of patients
with PTC (27). Activating RET translocations also occur, but
much less frequently, in patients with lung adenocarcinoma
and chronic myelomonocytic leukemia (28,29). Furthermore,
inactivating mutations occur throughout the RET oncogene in
patients with hereditary and sporadic Hirschsprung’s disease
(HD) (30,31).
At the Seventh InternationalWorkshop onMEN a group of
experienced clinicians and basic scientists developed the first
guidelines for managing patients with hereditary MTC (2).
Subsequently, with the discovery of additional oncogenic
RET mutations and their associated phenotypes, it became
clear that the original guidelines needed modification.
Recently, the North American Neuroendocrine Tumor So-
ciety, the National Comprehensive Cancer Network, and the
American Thyroid Association (ATA) published guidelines
for the management of patients with sporadic MTC and he-
reditary MTC (3–5). Each of the four guidelines described
the disease phenotypes associated with specific RET muta-
tions in hereditary MTC and recommended timing of early
thyroidectomy based on the specific RET mutation. Three of
the groups used either the TNM designation of the American
Joint Committee on Cancer (AJCC), or terms such as Level
I, II, or III, or ‘‘high,’’ ‘‘higher,’’ or ‘‘highest,’’ to designate
progressive increases in aggressiveness of the MTC (2–4).
The aggressiveness was based on the development of MTC at
an early age, frequently in association with metastatic dis-
ease. The original ATA Guidelines used A, B, C, and D
designations to define categories of RETmutations associated
with increasing aggressiveness (fromA to D) of the MTC (5).
There has been confusion regarding the different ATA risk
categories. Therefore, the Task Force recommends that cat-
egory D be changed to a new category, ‘‘highest risk’’ (HST);
category C be changed to a new category, ‘‘high risk’’ (H);
and the A and B categories be combined into a new category,
‘‘moderate risk’’ (MOD). The ATA-HST category includes
patients with MEN2B and the RET codon M918T mutation,
the ATA-H category includes patients with RET codon C634
mutations and the RET codon A883Fmutation, and the ATA-
MOD category includes patients with RET codon mutations
other than M918T, C634, and A883F.
Table 2. Abbreviations Used for Medullary
Thyroid Cancer Management Guidelines
ACTH Adrenocorticotropic hormone
AJCC American Joint Committee on Cancer
ATA American Thyroid Association
CCH C-cell hyperplasia
CEA Carcinoembryonic antigen
CLA Cutaneous lichen amyloidosis
CRH Corticotropin-releasing hormone
CT Computed tomography (tomographic)
Ctn Calcitonin
EBRTa External beam radiation therapy
EMA European Medicines Agency
FDA U.S. Food and Drug Administration
FDG-PET 2-[Fluorine-18]fluoro-2-deoxy-D-glucose-
positron emission tomography
F-DOPA 18F-dihydroxyphenylalanine
FMTC Familial medullary thyroid cancer
FNA Fine-needle aspiration
FTC Follicular thyroid carcinoma
HD Hirschsprung’s disease
HIPAA Health Insurance Portability and
Accountability Act
HPTH Hyperparathyroidism
HR Hazard ratio
ICMA Immunochemiluminometric assay
IHC Immunohistochemical
IMRT Intensity-modulated radiation therapy
MEN Multiple endocrine neoplasia
MIBG Metaiodobenzylguanidine
MRI Magnetic resonance imaging
MTC Medullary thyroid carcinoma
NCT National Clinical Trial
OMIM Online Mendelian Inheritance in Man
PEG Percutaneous gastrostomy
PFS Progression-free survival
PGD Preimplantation genetic diagnosis
PHEO Pheochromocytoma
PTC Papillary thyroid carcinoma
PTH Parathyroid hormone
RAI Radioactive iodine
RECIST Response evaluation criteria in solid tumors
REMS Risk evaluation and mitigation strategies
RET REarranged during Transfection
protooncogene
SEER Surveillance, Epidemiology, and End Results
TKI Tyrosine kinase inhibitor
TNM Tumor, node, metastases
TSH Thyrotropin
US Ultrasound
VEGF Vascular endothelial growth factor
aMay include intensity-modulated radiation therapy.
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Since the discovery of the RET oncogene, over 100 muta-
tions, duplications, insertions, or deletions involving RET
have been identified in patients with hereditary MTC. The
most common RET germline mutations causing MEN2A
and MEN2B and the clinical aggressiveness of the MTC as-
sociated with the mutations are shown in Table 4. A complete
tabulation of RET germline mutations reported to date, in-
cluding single or multiple mutations, duplications, insertions
or deletions, and chromosomal rearrangements involving
RET, can be found in the Supplementary Information (Sup-
plementary Data are available online at www.liebertpub.com/
thy) and at the continually updated ARUP database website:
www.arup.utah.edu/database/MEN2/MEN2_welcome.php (32).
The risk designation for sporadic MTC is based on the
AJCC tumor (T), node (N), and metastases (M) categories.
& RECOMMENDATION 1
The current ATA risk categories for hereditary MTC
should be changed. The current level D category
should be changed to a new category, ‘‘highest risk’’
(HST) that includes patients with MEN2B and the
RET codon M918T mutation. The current level C cate-
gory should be changed to a new category, ‘‘high risk’’
(H) that includes patients with the RET codon C634
mutations and the RET codon A883F mutation. The
current level A and B categories should be combined
Table 3. Strength of Recommendations Based on Available Evidence
Rating Definition
A Strongly recommends. The recommendation is based on good evidence that the service or intervention can
improve important health outcomes. Evidence includes consistent results from well-designed,
well-conducted studies in representative populations that directly assess effects on health outcomes.
B Recommends. The recommendation is based on fair evidence that the service or intervention can improve
important health outcomes. The evidence is sufficient to determine effects on health outcomes, but the
strength of the evidence is limited by the number, quality, or consistency of the individual studies;
generalizability to routine practice; or indirect nature of the evidence on health outcomes.
C Recommends. The recommendation is based on expert opinion.
D Recommends against. The recommendation is based on expert opinion.
E Recommends against. The recommendation is based on fair evidence that the service or intervention does
not improve important health outcomes or that harms outweigh benefits.
F Strongly recommends against. The recommendation is based on good evidence that the service or
intervention does not improve important health outcomes or that harms outweigh benefits.
I Recommends neither for nor against. The panel concludes that the evidence is insufficient to recommend
for or against providing the service or intervention because evidence is lacking that the service or
intervention improves important health outcomes, the evidence is of poor quality, or the evidence is
conflicting. As a result, the balance of benefits and harms cannot be determined.
Adapted from the U.S. Preventive Services Task Force, Agency for Healthcare Research and Quality.
Table 4. Relationship of Common RET Mutations to Risk of Aggressive MTC in MEN2A
and MEN2B, and to the Incidence of PHEO, HPTH, CLA, and HD in MEN2A
RET mutationa Exon MTC risk levelb Incidence of PHEOc Incidence of HPTHc CLAd HDd
G533C 8 MOD + - N N
C609F/G/R/S/Y 10 MOD + / ++ + N Y
C611F/G/S/Y/W 10 MOD + / ++ + N Y
C618F/R/S 10 MOD + / ++ + N Y
C620F/R/S 10 MOD + / ++ + N Y
C630R/Y 11 MOD + / ++ + N N
D631Y 11 MOD +++ - N N
C634F/G/R/S/W/Y 11 H +++ ++ Y N
K666E 11 MOD + - N N
E768D 13 MOD - - N N
L790F 13 MOD + - N N
V804L 14 MOD + + N N
V804M 14 MOD + + Y N
A883F 15 H +++ - N N
S891A 15 MOD + + N N
R912P 16 MOD - - N N
M918T 16 HST +++ - N N
aThe references for each of the RET mutations can be found in the Supplementary Information, where all reported RET mutations in MTC
are listed.
bRisk of aggressive MTC: MOD, moderate; H, high; HST, highest.
cIncidence of PHEO and HPTH: + =*10%; ++ =*20%–30%;+++ =*50%.
dY, positive occurrence; N, negative occurrence.
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into a new category ‘‘moderate risk’’ (MOD) that include
patients with hereditary MTC and RET codon mutations
other than M918T, C634, and A883F. Grade C Re-
commendation
[C] CLINICAL CHARACTERISTICS AND RELATIONSHIP
BETWEEN GENOTYPE AND PHENOTYPE IN PATIENTS
WITH SPORADIC MTC AND PATIENTS
WITH HEREDITARY MTC
[C-1] Sporadic MTC
Sporadic MTC usually occurs between the fourth and sixth
decades of life (33). Central and lateral compartment lymph
node metastases are present respectively in 14% and 11%
of patients with T1 tumors and in 86% and 93% of patients
with T4 tumors (34). Unfortunately, 70% of patients with
MTC who present with a palpable thyroid nodule have cer-
vical metastases and 10% have distant metastases (35). On
univariate analysis prognosis is directly related to patient age
at diagnosis, male sex, the presence of local tumor invasion,
the presence of lymph node metastases, and the presence of
distant metastases. On multivariate analysis, however, only
age and stage of disease at the time of diagnosis are significant
independent prognostic factors (36,37). Ten-year survival
rates for patients with stages I, II, III, and IV MTC are 100%,
93%, 71%, and 21%, respectively (37). The clinical behavior
of sporadic MTC is unpredictable; however, some patients
with distant metastases may live for several years. In recent
decades there has been no significant trend toward an earlier
stage of disease at the time of diagnosis, as just under half of
the patients present with stage III or IV disease. Also, there has
been no significant increase in patient survival (38,39).
[C-2] Hereditary MTC
In 1968 Steiner and colleagues described a family with the
concurrence of MTC, pheochromocytoma (PHEO), hyperpa-
rathyroidism (HPTH), and Cushing’s syndrome. They sug-
gested that the entity be named multiple endocrine neoplasia
type 2 (MEN2) in contradistinction to the previously described
hereditary disease, MEN1 (40,41). The syndrome that Steiner
and associates described is now known as MEN2A (Online
Mendelian Inheritance in Man [OMIM], #171400, incidence
1/1,973,500) (1). In retrospect the earliest documented family
with MEN2A was from Sweden and concerned a kindred
dating to the early 1700s (42). A branch of the Swedish kindred
immigrated to the United States and was studied extensively
by Tashjian and colleagues (9). Asmore families were studied,
the disease spectrum of MEN2A has expanded to include two
variants: patients with associated cutaneous lichen amyloid-
osis (CLA) and patients with associated HD (43,44).
The MEN2B syndrome (OMIM #162300, incidence 1/
38,750,000) variably described by Williams and Pollock,
Schimke and colleagues, andGorlin and associates, accounts for
5% of hereditary MTCs (1,45–47). Patients with MEN2B de-
velop MTC and PHEOs and exhibit a recognizable phenotype.
Farndon and associates described FMTC [OMIM #155240]
(48). Originally, strict criteria defined the diagnosis of FMTC:
more than 10 family members with MTC, multiple carriers or
affected members over 50 years of age, and an adequate
medical history (particularly in older family members) to ex-
clude the presence of PHEO and HPTH (2). A less rigid def-
inition was the presence in at least four family members of
MTC without other manifestations of MEN2A (49). Defining
and distinguishing FMTC fromMEN2A has been challenging,
with the controversy focusing on the concern that premature
categorization of a family with FMTC could result in failure to
identify a PHEO (50). This is illustrated by families with the
RET codon G533C mutation in exon 8. In 2003 a large six-
generation Brazilian family with this mutation, including 76
gene carriers (29 with MTC and none with PHEO or HPTH),
was described as having FMTC (51). Also, two Greek families
with theRET codonG533Cmutation, including 20 carriers, six
with MTC and none with PHEO or HPTH, were reported as
having FMTC (52). Subsequently, a patient in the Brazilian
kindred developed a PHEO, and investigators in Greece and
the United States reported additional families with the RET
codon G533C mutation who had MTC and PHEO, thus clar-
ifying that this mutation is associated with MEN2A (53–56).
At present, there are only three documented families that meet
the original strict criteria described for FMTC (2,57–59).
Currently, the opinion of most clinical investigators is that
FMTC should not be a freestanding syndrome; rather it
should represent a variant along the spectrum of disease ex-
pression in MEN2A. The Task Force agrees that FMTC
should not be defined as a form of hereditary MTC distinct
from MEN2A and MEN2B (2,49). Rather it should be rec-
ognized as a variant of MEN2A to include families with only
MTC who meet the original strict criteria for FMTC, small
families of at least two generations with at least two, but less
than 10, subjects with RET germline mutations, small fami-
lies in which two or fewer members in a single generation
have RET germline mutations, and single individuals with a
RET germline mutation (see Supplementary Information).
& RECOMMENDATION 2
There should be two MEN2 syndromes: MEN2A and
MEN2B.WithinMEN2A,which accounts for 95%ofMEN2
cases, there should be four variants: classical MEN2A (re-
presented by the uniform presence of MTC and the less
frequent occurrence of PHEO, or HPTH, or both), MEN2A
with CLA, MEN2A with HD, and FMTC (families or indi-
viduals with RET germline mutations who have MTC but
neither PHEOs nor HPTH). Grade C Recommendation
[C-2-1] MEN2A
[C-2-1-1] Classical MEN2A. Classical MEN2A is the
most common MEN2A variant and in 95% of patients RET
germline mutations occur in codons 609, 611, 618, or 620 of
exon 10 or codon 634 of exon 11 (60). Virtually all patients
develop MTC and lower numbers develop PHEOs or HPTH,
the frequency of each depending on the specific RET muta-
tion. For example RET codon 634 mutations are associated
with a high penetrance of PHEO, which in one study in-
creased with age, being 25% by age 30 years, 52% by age 50
years, and 88% by age 77 years (61). There is a much lower
penetrance of PHEO in patients with exon 10 RET codon
mutations (609 [4%–26%], 611 [10%–25%], 618 [12%–
23%], and 620 [13%–24%]) (62). The PHEOs are almost
always benign and are usually multicentric, bilateral, and
confined to the adrenal gland. The tumors are usually asso-
ciated with diffuse nodular adrenal medullary hyperplasia,
particularly in patients with RET germline mutations in
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codons 918 and 634 (63). Patients with MEN2A and a uni-
lateral PHEO usually develop a contralateral PHEOwithin 10
years (63). Prior to the development of biochemical and ge-
netic tests to detect MTC in patients with classical MEN2A,
the most common cause of death was PHEO not MTC (64).
The HPTH in patients with classical MEN2A is usually mild
and associated with few if any symptoms. From one to four
parathyroid glands may be enlarged. A RET codon 634 mu-
tation is associated with a moderate penetrance of HPTH (up
to 30%), and RETmutations in codons 609, 611, 618, and 620
are associated with a penetrance between 2% and 12%
(62,65). For practical reasons, screening for HPTH should be
done concurrently with screening for PHEO.
There are very rare families with features of classical
MEN2A who have no identifiable RET germline mutation. In
this situation the diagnosis of classical MEN2A can be made
if one or more first-degree relatives have characteristic clin-
ical features of the entity.
[C-2-1-2] MEN2A and CLA. CLA is a rare disorder that
usually occurs sporadically but may present in a hereditary
pattern, either as a separate entity or in association with other
diseases, one of which is MEN2A (66). The CLA in MEN2A
is characterized by dermatological lesions that are particu-
larly evident in the scapular region of the back corresponding
to dermatomes T2–T6 (43,67). The classic symptom of CLA
is intense pruritus that improves with sun exposure and
worsens during periods of stress. Hyperpigmented lesions
develop later, apparently secondary to scratching. The in-
citing lesion appears to be notalgia paresthetica, a sensory
neuropathy involving the dorsal spinal nerves (66). The CLA
may be present at a young age and prior to the onset of
clinically evident MTC, thus serving as a precursor for the
syndrome (43,67). The CLA in patients with MEN2A occurs
almost exclusively in patients with the RET codon 634 mu-
tation, although it has been reported in a patient with a codon
804 mutation (68,69). In one study CLA, or regional pruritus
without CLA, occurred in 36% of patients with the RET co-
don 634 mutation (67). PHEOs and HPTH occur in this
variant with the same frequency as in classical MEN2A (67).
Moisturizing lotions and creams, local corticosteroids,
systemic antihistamines, and phototherapy usually provide
incomplete symptom relief of the pruritus. Three patients
with advanced MTC and CLA experienced rapid disappear-
ance of the skin disease in response to treatment with the ty-
rosine kinase inhibitor (TKI), vandetanib; however, the CLA
reappeared following dose reduction (M. Schlumberger and R.
Gagel; personal communication, May 2008 and June 2009).
[C-2-1-3] MEN2A and HD. RET germline mutations are
present in 50% of patients with hereditary HD and in 15%–
20% of patients with sporadic HD (30). Over 100 RET mu-
tations have been described in HD, including microdeletions
and insertions, nonsense or missense point mutations, splic-
ing mutations, or deletions encompassing segments of the
RET gene (31). The RET mutations in patients with MEN2A
and HD are point mutations involving codons in exon 10: 609
(15%), 611 (5%), 618 (30%), and 620 (50%) (70,71). HD
occurs in approximately 7% of patients with MEN2A (72,73).
Conversely, 2%–5% of patients with HD have MEN2A
(73,74). HD is almost always apparent shortly after birth;
however, it is important to exclude HD in older patients with
MEN2A and exon 10 RET mutations who have colon symp-
toms suggestive of HD. Conversely, patients with HD who
have exon 10 RETmutations should be evaluated for MEN2A.
It seems paradoxical that MEN2A and HD should occur
together, since the RET mutations associated with HD are
‘‘loss of function,’’ while the RET mutations associated with
MEN2A are ‘‘gain of function.’’ The generally accepted ex-
planation for this dual occurrence is that constitutive activation
of RET is sufficient to trigger neoplastic transformation of the
C-cells and adrenal chromaffin cells, yet insufficient to gen-
erate a trophic response in the precursor neurons due to a lack
of expression of the RET protein at the cell surface (75).
[C-2-1-4] FMTC. FMTC is characterized by the pres-
ence of a RET germline mutation in families with MTC (or
single individuals with MTC and no family history of MTC)
who develop neither PHEOs nor HPTH.
[C-2-2] MEN2B
In patients with MEN2B the MTC often presents in infancy
and is highly aggressive, metastasizing early to regional lymph
nodes and beyond. Approximately 75% of MEN2B cases are
sporadic and affected patients have de novo RET mutations,
while 25% of cases occur in families with previous or current
manifestations of MEN2B. Approximately 95% of patients
withMEN2B have RET germline mutations in exon 16 (codon
M918T) and fewer than 5% have RET germline mutations in
exon 15 (codon A883F) (16,18,76,77). Almost all published
reports on MEN2B concern patients with the RET codon
M918Tmutation and little is known about the clinical behavior
of patients with the RET codon A883F mutation. Recent re-
ports, however, suggest that patients with the A883F codon
mutation have a less aggressive MTC compared to patients
with the M918T codon mutation (78).
Approximately 50% of patients with MEN2B develop
PHEOs. They also have a unique physical appearance char-
acterized by a typical facies, ophthalmologic abnormalities
(inability to make tears in infancy, thickened and everted eye-
lids, mild ptosis, and prominent corneal nerves), skeletal mal-
formations (marfanoid body habitus, narrow long facies, pes
cavus, pectus excavatum, high-arched palate, scoliosis, and
slipped capital femoral epiphyses), and a generalized gang-
lioneuromatosis throughout the aerodigestive tract. Most pa-
tients have abdominal symptoms characterized by bloating,
intermittent constipation, and diarrhea, and some patients re-
quire surgery for intestinal obstruction (79,80). It is important to
establish the diagnosis ofMEN2B at an early agewhen there is a
possibility that thyroidectomy will be curative. However, the
reality is that most patients with MEN2B are diagnosed when
theMTC is clinically evident and too advanced to be cured (81).
A rare group of patients have atypical MEN2B that develops
around 20 to 30 years of age. The patients have double RET
germline mutations appearing in tandem on the same allele and
involving RET codon V804M and either RET codon Y806C,
S904C, E805K, or Q781R (82–85). Evaluation of the tandem
mutations by in vitro and in silico analysis provides information
about their transforming ability (prediction scores). Using this
methodology, each of the four reported double RET mutations
had high transforming ability compared to the single mutations
of the pairs, supporting the presence of amore aggressiveMTC.
Similar double RET germline mutations have been identified in
families with the FMTC variant of MEN2A (86,87).
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[D] DIRECT DNA ANALYSIS TO DETECT MUTATIONS
IN THE RET PROTOONCOGENE
A sequence change in the RET gene is considered to be a
causative MEN2 mutation if it segregates with the clinical
expression of disease within a family including at least two
affected individuals having theMEN2AorMEN2B phenotype.
In contrast, benign germline RET sequence changes not caus-
ative of MEN2 are considered polymorphisms; for example, p.
G691S, p. L769L, p. S836S, p. S904S, or intron 14 c.2608-
24G>A. If insufficient clinical information is available (e.g.,
only one gene carrier with disease or incidentally detected RET
sequence changes without disease manifestations) a prelimi-
nary classification of ‘‘variant of unknown significance’’ is
suggested. Classification of risk groups in patients with
MEN2A, based on aggressiveness of MTC or penetrance es-
timates of PHEO or HPTH, is only meaningful if adequate
numbers of patients are available for valid risk assessment.
Currently, more than 600 international laboratories offer
molecular genetic testing, biochemical testing, and cytoge-
netic testing for more than 3000 inherited disorders (88). Many
of the laboratories offer prenatal diagnosis. Screening for he-
reditary MTC is relatively simple when one knows the RET
germline mutation carried in the family because a targeted
approach can detect the specific mutated RET allele in at-risk
family members. In new families with hereditary MTC, in
whom the specific RET mutation is unknown, the usual strat-
egy is to sequence initially the most commonly mutated RET
cysteine codons in exons 10 and 11 (C609, C611, C618, C620,
C630, and C634) as well as additionalRET codon mutations in
exons 13, 14, 15, and 16. A few laboratories include exon 8
(89). Some laboratories sequence the entire RET coding re-
gion, although the cost increases as the extent of sequencing
increases. The expense of sequencing has decreased markedly
over the last few years and will continue to do so, such that
soon it may be relatively inexpensive to sequence the entire
RET coding region as the first step in screening. Other labo-
ratories use a two-tiered approach, starting with analysis of the
most commonlymutated ‘‘hotspot’’ exons. At the request of the
ordering physician, the laboratories sequence the remaining
RET exons if the initial analysis is negative or if the patient’s
phenotype is inconsistent with the RET mutation initially
identified. However, tiered approaches may fail to detect rare
RET double or multiple mutations that would be identified by
sequencing the entire RET coding sequence. For example, as
already mentioned, codon 804 mutations occur in conjunction
with a second RET mutation in rare cases of MEN2B or the
FMTC variant of MEN2A. Also, in rare patients withMEN2A,
there are doubleRETmutations or even triple or quadrupleRET
mutations that target residues other than codon V804 (89–93).
The occurrence of multiple RET mutations may cause an un-
usual clinical phenotype compared to that seen with the cor-
responding single RET mutations. This situation has been
reported recently in five kindreds from Brazil featuring coin-
cident Y791F and C634Y RET codon mutations (94,95).
& RECOMMENDATION 3
The recommended method of initial testing for MEN2A is
either a single or multi-tiered analysis to detect RET mu-
tations in exon 10 (codons 609, 611, 618, and 620), exon
11 (codons 630 and 634), and exons 8, 13, 14, 15, and 16.
Grade B Recommendation
& RECOMMENDATION 4
Sequencing of the entire coding region should be reserved
for situations in which no RET mutation is identified or
there is a discrepancy between the MEN2 phenotype and
the expected genotype. Grade B Recommendation
& RECOMMENDATION 5
Patients with theMEN2Bphenotype should be tested for the
RET codon M918T mutation (exon 16), and if negative, the
RET codon A883F mutation (exon 15). If there are no mu-
tations identified in these two exons the entire RET coding
region should be sequenced. Grade B Recommendation
[D-1] Direct DNA analysis to detect RET germline
mutations in patients with apparent sporadic MTC
Importantly, 1%–7% of patients with presumed sporadic
MTC actually have hereditary disease (96,97). Patients with
sporadic MTC should have genetic counseling and direct DNA
analysis to detect a mutated RET allele. Patients found to have a
RET germline mutation should be evaluated, and their first-
degree relatives shouldbeofferedgenetic counselingandgenetic
testing. Genetic counseling and genetic testing should also be
considered in populations at high risk for hereditary MTC, such
as patients with CLA and patients with HD who have exon 10
mutations. In 5%–9% of patients with MEN2A, and the large
majority of patients with MEN2B, the RET mutation arises de
novo and almost always from the paternal allele (98,99). At
present there is no indication for evaluating the thyroid tumors of
patients with sporadic MTC for the presence of somatic HRAS,
KRAS, or NRASmutations, or the RET codonM918T mutation.
& RECOMMENDATION 6
Patients with presumed sporadic MTC should have genetic
testing to detect a germline RET mutation. If a RET mu-
tation is found the patient should have genetic testing.
Grade B Recommendation
& RECOMMENDATION 7
Genetic counseling and genetic testing for RET germline
mutations should be offered to
a) first-degree relatives of patients with proven hereditary
MTC,
b) parents whose infants or young children have the
classic phenotype of MEN2B,
c) patients with CLA, and
d) infants or young children with HD and exon 10 RET
germline mutations, and adults with MEN2A and exon
10 mutations who have symptoms suggestive of HD.
Grade B Recommendation
& RECOMMENDATION 8
Other than for academic reasons or physician preference, it
is not standard practice to analyze tumors of patients with
sporadicMTC for somaticHRAS,KRAS, orNRASmutations,
or the RET M918T mutation. Grade C Recommendation
& RECOMMENDATION 9
In very rare families who meet the clinical criteria for
MEN2Aor 2B, despite negative sequencing of the entireRET
coding region, the relatives at risk should be periodically
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screened by conventional methods for MTC, PHEO, and
HPTH. After the initial evaluation, screening should continue
at 1- to 3-year intervals. Grade C Recommendation
[E] ETHICAL CONSIDERATIONS
FOR GENETIC SCREENING
[E-1] Adults
In a physician–patient relationship the legal and ethical
duty to warn identifiable third parties of foreseeable harm
was established in Tarasoff v. Regents of the University of
California in which the court held that ‘‘privacy ends where
the public peril begins’’ (100). In Tarasoff, the failure to warn
a woman about premeditated homicide by her boyfriend, who
had confided the plan to his University of California psy-
chologist, led to a new standard for warning third parties who
wittingly or unwittingly may be an ‘‘agent of harm.’’ The
Tarasoff ruling is a translational health law precedent that has
been widely applied to numerous clinical contexts.
In the Pate v. Threlkel case, a surgeon was found negligent
for failing to warn his patient that her children were at risk for
hereditary MTC (101). The court held: ‘‘Physicians may owe
a legal duty to the children of a patient when they are iden-
tified beneficiaries of the prevailing standard of care.’’ This
ruling reinforced the identification of ‘‘at-risk’’ third parties
and defined boundaries for physicians in determining who
should be warned (102).
In Safer v. the Estate of Pack, another case assessing duty to
warn in a family with familial polyposis syndrome, it was es-
tablished that physicians could not satisfy the duty to warn
merely by informing the patient of possible risks (103). They
must take ‘‘reasonable steps to guarantee that immediate family
members are warned’’ (104). Given the complexity of the in-
formation, and what is known about occult psychosocial bar-
riers to screening, it should not be expected that patients are
qualified to explain the genetic aspects of their disease or to
discuss potential therapies to family members when they lack
the scientific or medical competence to do so. The patient,
however, needs to participate in identifying at-risk relatives for
possible screening. An ethical dilemma arises only when the
patient refuses permission to contact at-risk relatives or states
that he does not wish to disclose his health information to
family members. In this context, it is usually permissible eth-
ically, or is even obligatory, to warn third parties without the
patient’s consent. In such a dilemma a case-based approach is
needed with involvement of clinical ethicists, social workers,
and legal counsel. There are proposed criteria for evaluating the
permissibility of duty to warn, which include gravity, proba-
bility, imminence of harm, identifiability of at-risk individuals,
probability that intervention can mitigate harm, the degree to
which means of maintaining confidentiality have been ex-
hausted, andwhether the patient is an agent of harm.Most cases
of genetic risk in cancer do not satisfy all of these criteria;
however, hereditary MTC satisfies each of them (102,104).
There is no clear guidance from professional societies on the
matter of informing family members at risk when the affected
relative is reluctant to do so. TheAmericanMedical Association
and the American Society of Clinical Oncology recommend
restricting initial disclosure of test results to the person who had
the test, but encourage working with the patient to identify and
notify at-risk familymembers (105,106). On the other hand, The
American Society of Human Genetics supports disclosure of
genetic information under exceptional circumstances to at-risk
family members, even though it might be inconsistent with the
wishes of the patient (107). On a somewhat different matter, the
American College of Medical Genetics states that disclosure of
RET mutations should be mandatory when found incidentally
during exom and whole genome sequencing (108). Earlier lit-
erature on HIPAA is less clear about whether breaching HIPAA
in the MTC context places the physician at risk (109,110).
& RECOMMENDATION 10
Regarding hereditary MTC, the duty to warn a competent
and capacitated patient or surrogate decision maker of the
risk that an inherited RET mutation may pose to family
members is a standard of care. This warning is ideally
fulfilled in the setting of genetic counseling and should
include a request for the patient to participate in identify-
ing at-risk relatives. The ‘‘duty to warn’’ discussion should
be a part of the informed consent process, in which there is
full disclosure of the seriousness of the disease and
available forms of prevention and treatment. When a pa-
tient refuses to notify relatives or legal dependents of their
risks, the physician should consider whether he has an
ethical duty or obligation to warn family members at risk.
He should consult a trained clinical ethicist either at his
medical center or another medical facility or contact the
American Thyroid Association Ethics Committee for
guidance. Grade A Recommendation
[E-2] The pediatric population
In the pediatric population the concern lies in identifying
children at risk for inheritingMEN2 from a parent who refuses
to disclose to the child their specific risks and the available
preventative or therapeutic options. It may be necessary to
involve state officials and the courts to resolve such issues in
order to protect the child. Regarding informed consent in a
pediatric context, physicians should refer to published state-
ments by professional organizations and clinical ethicists:
Pediatric Ethics Guidelines for Inherited Medullary Thyroid
Cancer and the American Pediatric Association Committee on
Bioethics statement: Informed Consent, Parental Permission,
and Assent in Pediatric Practice (111,112).
& RECOMMENDATION 11
With pediatric patients who have not reached the age of
consent, it may be necessary for physicians to seek state
intervention to prevent harm when there is parental refusal
to inform their children of the risk of developing a ma-
lignant tumor. Practitioners with pediatric populations
should consult published documents for guidance. Grade
A Recommendation
[E-3] Reproductive options of RET
mutation carriers
Prenatal and pre-implantation testing is available to indi-
viduals with MEN2 (113–116). Prenatal testing can be per-
formed in the first or second trimester by chorionic villus
sampling or amniocentesis, respectively. Also, it is possible
to perform prenatal testing on fetal blood cells obtained from
maternal blood (117). High-resolution melting genotype
analysis can detect RET mutations in the serum of patients
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withMEN2A. Recently, the technique was applied prenatally
to detect a RET codon C634Y mutation in a fetus by identi-
fying the mutation in blood from the unaffected pregnant
mother whose husband had a C634Y codon mutation (118).
Such testing might be offered to couples in which only the
father has hereditary MTC and the parents wish to know the
mutational status of the fetus.
Pre-implantation genetic diagnosis (PGD) is an in vitro
fertilization technique that isolates embryonic cells for single-
siteRET testing. The procedure involves removal of one or two
cells from an eight-cell blastocyst followed by sequence
analysis of the DNA of the removed cells to determine if aRET
mutation is present. Nonmutated embryos are then implanted
into the mother, providing the opportunity to eliminate the
disease gene from the family (119). Successful delivery of an
unaffected child from an affected mother has been achieved
with this technique and advances with the technology have led
to higher pregnancy rates (120,121).
The role of PGD in adult-onset disease remains contro-
versial. It is generally offered to patients with syndromes
characterized by a young age of onset with significant cancer
risk and associated morbidity or mortality. With an average
age ofMTC onset well under 30 years of age—much lower in
patients with MEN2B—and a risk of PHEO up to 50%, PGD
may be an option for parents if one of them has MEN2 (es-
pecially those with RETmutations in codons 634 and 918). In
practice, however, there is little evidence that clinicians or
patients have availed themselves of this technology over the
past decade, despite its widespread use for other genetic
disorders. Two possible reasons may explain the lack of
participation. First is the perception that the MTC in
youngsters with MEN2A can be managed by timely surgical
intervention. There are children with MEN2Awho have been
treated by prophylactic thyroidectomy and are alive without
evidence of recurrent MTC decades later. Second, it can be
very difficult to convince young parents to spend a substantial
amount of money for PGD and in vitro fertilization (usually
not covered by insurance), when there is the alternative of
managing the individual manifestations of the disease (usu-
ally covered by health insurance) if and when they occur.
Nonetheless, it is important for the physician to make patients
aware of this technology or refer them to a genetic counselor
with expertise in this area. There should be appropriate
documentation of the exchange of information.
The surgical management of children with MEN2B is
challenging, and few are cured. Therefore, young parents (one
of whom has MEN2B) planning to have children should be
informed of the availability of in vitro fertilization and PGD.
[E-4] Ethical considerations for preconception
and prenatal counseling
Preconception counseling and prenatal testing are avail-
able to individuals with hereditaryMTC.While a patient may
not wish to proceed with prenatal pre-implantation diagnosis,
the clinician has both a legal and ethical duty to warn in the
prenatal context as well. The courts held inMolloy v. Meier, a
case concerning Fragile X syndrome, that physicians have
a duty to warn of genetic harms and to inform patients of
all available prenatal medically appropriate options (122).
Failure to warn in a prenatal context could lead to allegations
of wrongful conception, wrongful life, or even wrongful
birth, in which case the parents or the offspring could sue the
physician for damages related to a foreseeable and serious
genetic disease or condition.
Parents who do not wish to have prenatal RET mutation
testing should be offered genetic counseling and genetic
testing of their child, the timing to be determined by the
treating physician in consultation with the child’s parents
(112). The foregoing statement assumes that the fetus is a
patient. Fetuses are not always patients if the mother does not
intend to complete the pregnancy.
& RECOMMENDATION 12
The duty to warn of genetic risk extends to both precon-
ception and prenatal contexts. Genetic counseling about
the options of pre-implantation or prenatal diagnostic
testing should be considered for all RET mutation carriers
of childbearing age, particularly those with MEN2B.
Parents who do not wish to have prenatal RET mutation
testing should be offered genetic counseling and informed
of the availability of genetic testing of their child to detect
a mutated RET allele. This is particularly important for
mutations associated with the onset of MTC before 5 years
of age. Grade A Recommendation
[F] SECRETORY PRODUCTS OF MTC
The C-cells of the thyroid gland secrete several hormones
or biogenic amines, including adrenocorticotropic hormone
(ACTH), B-melanocyte stimulating hormone, Ctn, carcinoem-
bryonic antigen (CEA), chromogranin, histaminase, neurotensin,
and somatostatin (123–128).Of these secretory products, Ctn and
CEA are valuable tumormarkers in patients withMTC, and their
serum concentrations are directly related to the C-cell mass.
[F-1] Calcitonin
Calcitonin is a 32–amino acidmonomeric peptide that results
from cleavage and post translational processing of procalcito-
nin, a precursor peptide derived from preprocalcitonin (129).
Over the past decade commercial assays for measuring Ctn
have progressed to the newest immunochemiluminometric as-
says (ICMAs) that are highly sensitive and specific for mono-
meric Ctn. With ICMAs, cross-reactivity with procalcitonin or
other calcitonin-related peptides is largely eliminated. This is
important because sepsis or other general inflammatory con-
ditions may cause profound elevations of procalcitonin in tis-
sues that do not normally transcribe the Ctn gene (130,131).
Serum Ctn levels may be increased in patients with chronic
renal failure, and other ailments, such as HPTH, autoimmune
thyroiditis, small cell and large cell lung cancers, prostate
cancer, mastocytosis, and various enteric and pulmonary neu-
roendocrine tumors (132–139). The serumCtn levels in patients
with the various nonthyroid malignancies do not increase in
response to calcium or pentagastrin stimulation, and compared
toMTC, the tumors usually produce less Ctn per gram of tissue.
Heterophilic antibodies (human antibodies with a broad
reactivity with antibodies of other animal species) cause
falsely elevated (and rarely falsely lower) serum Ctn levels
(140). The ‘‘hook effect’’ refers to the detection of falsely
low analyte levels in the immunoassay resulting from very
high serum levels of Ctn (as occurs in patients with widely
disseminated MTC), which saturate the binding capacity of
the antibody (141). The hook effect is less likely to occur with
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ICMAs, but should remain a concern in patients with a large
tumor burden and surprisingly low serum Ctn levels.
Depending on the assay, 56%–88% of normal subjects have
serum Ctn levels below the functional sensitivity, while 3%–
10% have Ctn levels greater than 10 pg/mL (142). Current
reference ranges for serum Ctn are higher in men compared
with women, almost certainly due to the larger C-cell mass in
men (143,144). Using the Advantage system (Nichols Institute
Diagnostics, San JuanCapistrano, CA), Basuyau and associates
found the 95th percentile for serum Ctn levels to be 5.2 ng/L in
women and 11.7 ng/L inmen (143). There may be variability in
Ctn measurements among commercial assays, emphasizing the
imperative of evaluating individual patient samples in the same
assay before and after thyroidectomy and during treatment for
advanced disease. Laboratories should notify clinicians when
there is a change in assay methodology, including the reference
ranges of the new Ctn assay. The current revised MTC
guidelines do not specify reference ranges of basal or stimu-
lated serum Ctn levels. Based on studies of large numbers of
normal patients and patients with MTC, individual laboratories
may set their own criteria defining reference ranges for basal
and elevated serum Ctn levels.
In studies evaluating serum levels of Ctn and procalcitonin
in patients with MTC, Ctn was found to have equal or su-
perior diagnostic accuracy. However, a high procalcitonin
to Ctn ratio was correlated with an increased risk of pro-
gressive disease and a shortened progression-free survival
(PFS), potentially useful in predicting prognosis (145,146).
Although of interest, physicians rarely use serum procalci-
tonin levels in the management of patients with MTC.
There are sparse data on serum Ctn levels in young chil-
dren. Previous studies have shown that serumCtn concentrations
are particularly high during the first week of life and in low-
birthweight children and premature infants (143). Basuyau and
colleagues proposed a reference range of less than 40pg/mL in
children less than 6 months of age and less than 15pg/mL in
children between 6 months and 3 years of age. The highest
serum Ctn value observed in their series was 75pg/mL in a child
age 4.5months. A follow-up value 1month laterwas 32.4 pg/mL
(143). Serum Ctn values in children more than 3 years of age
were indistinguishable from those observed in adults.
Administrating potent secretagogues, such as intravenous
calcium or pentagastrin, may increase the sensitivity of Ctn
testing. There are mild but unpleasant side effects associated
with the infusion of these agents, although they are less both-
ersome with calcium. In some studies pentagastrin was a more
potent secretagogue than calcium, while in other studies the
converse was true (147–150). Some clinical investigators feel
that the sensitivity of the ICMA is such that provocative testing
is no longer necessary; however, others consider provocative
testing useful in determining the timing of thyroidectomy in
children who have inherited a mutated RET allele, in the eval-
uation of patients for persistent or recurrent MTC following
thyroidectomy, and for detecting MTC in patients with nodular
goiters (148,150). It is critical that clinicians who use provoc-
ative testing establish clear reference guidelines for abnormal
serum Ctn levels in their clinics, a more challenging task than
establishing reference guidelines for abnormal basal Ctn levels.
& RECOMMENDATION 13
Clinicians should be aware that falsely high or low serum
Ctn levels might occur with a variety of clinical diseases
other than MTC. They should consider this possibility
when serumCtn levels are disproportionate to the expected
clinical findings. Grade C Recommendation
& RECOMMENDATION 14
In interpreting serum Ctn data, clinicians should be aware
that Ctn levels are markedly elevated in children under 3
years of age, especially under 6 months of age. Also, Ctn
levels are higher in males compared with females. Grade B
Recommendation
[F-2] Carcinoembryonic antigen
CEA is not a specific biomarker for MTC. Primarily for this
reason, and also because serum CEA levels do not increase
following calcium or pentagastrin stimulation, measurement of
this tumor marker is not useful in the early diagnosis of MTC.
Determination of serum CEA levels is useful for evaluating
disease progression in patients with clinically evidentMTC and
for monitoring patients following thyroidectomy (151).
False elevation of serum CEA may result from hetero-
philic antibodies, smoking tobacco, or other conditions,
such as gastrointestinal tract inflammatory disease, benign
lung disease, or a host of nonthyroid malignancies. In pa-
tients with MTC simultaneous elevations of serum CEA and
Ctn levels indicate disease progression. Some patients with
progressive disease have increasing serum CEA levels as-
sociated with stable or declining serum Ctn levels. This is
considered an indication of poorly differentiated MTC and
is supported by CEA and Ctn immunohistochemistry find-
ings (152). In one study, CEA and Ctn were expressed in
almost every MTC cell. This was especially true for C-cell
hyperplasia (CCH), microscopic MTC, and gross MTC
confined to the thyroid. By contrast, there was an inverse
relationship between CEA and Ctn staining in the tumors of
patients with invasive or metastatic MTC. The most ag-
gressive tumors had persistent and intense CEA staining,
but minimal if any Ctn staining. It was suggested that CEA
is a marker for early epithelial differentiation and therefore
retained, while Ctn is a late marker for terminal differenti-
ation and therefore lost (152).
Rarely, patients with advanced MTC have normal or low
serum levels of Ctn and CEA. This unusual state represents
either a misdiagnosis or advanced dedifferentiation of the
MTC, in which case it conveys a poor prognosis (153,154). In
a study of 839 patients with sporadic MTC, seven (0.83%)
with advanced disease secreted neither Ctn nor CEA (155).
Poorly differentiated histology, a high Ki-67 proliferation
index (three patients), and a high proportion of RET codon
M918T mutated cells (four patients) characterized the ag-
gressive biological behavior of the MTC. The prognosis of the
patients with nonsecretory MTC varied between intermediate-
term survival (12.5 years) and rapid progression leading to
death within 1.75 years after diagnosis (155).
& RECOMMENDATION 15
Basal levels of serum Ctn and CEA should be measured
concurrently. In patients with advanced MTC, a marked
elevation in the serum CEA level out of proportion to a
lower serum Ctn level or normal or low levels of both
serum Ctn and CEA indicate poorly differentiated MTC.
Grade B Recommendation
REVISED ATA MANAGEMENT GUIDELINES FOR MTC 577
[G] MORPHOLOGICAL EXAMINATION
OF AN EXCISIONAL BIOPSY
OR THE THYROIDECTOMYSPECIMEN
As the ultimobranchial bodies migrate from the neural
crest during embryogenesis, they become entrapped within
the middle and upper poles of each thyroid lobe. There, they
give rise to C-cells, which are much more numerous in males
compared with females (144). Unlike other thyroid tumors,
which arise from follicular cells, MTC is a neuroendocrine
tumor. It is classified as a thyroid tumor because of its ana-
tomical location.
Macroscopically, MTC is firm and either white, tan, or red
in color. Sporadic MTC usually occurs as a solitary unilateral
tumor, whereas hereditary MTC is usually multicentric and
bilateral. On histological examination the MTC cells are
typically round, polyhedral, or spindle shaped and form
sheets or nests with peripheral palisading in a vascular stro-
ma. The amyloid material present in over half of MTCs is
actually composed of full-length Ctn (156).
There may be substantial variance in the histological ap-
pearance of MTC, such that it can be confused with PTC,
follicular thyroid carcinoma (FTC), paraganglioma, and even
lymphoma or sarcoma. Oncocytic change occasionally oc-
curs in these tumors, further confounding the diagnosis. The
MTC cells express cytokeratins, mainly CK7 and CK18,
NKX2.1 (TTF1), and chromogranin A, but the most impor-
tant diagnostic markers are Ctn and CEA.
Immunohistochemical (IHC) staining of Ctn may vary in
intensity and extent, but in its absence a diagnosis of MTC
should be questioned. The IHC reactivity of Ctn is often
reduced in undifferentiated tumors, whereas staining for
CEA is almost always strongly positive (152). The College
of American Pathologists has recommended synoptic re-
porting as a mechanism to ensure consistent and complete
documentation of cancer pathology. The synoptic data re-
commended for the evaluation of MTC are provided in
the Protocol for the Examination of Specimens from Pa-
tients with Carcinomas of the Thyroid Gland (available at
www.cap.org).
Occasionally, PTC or FTC occurs concurrently with MTC,
and although the relationship of the two components of the
complex tumors is controversial, their coexistence is thought
to represent a coincidental collision with intermingling of
neoplastic C-cells and follicular cells (157,158). A recent
study from Germany identified simultaneous MTC and PTC
in 26 (2.6%) of 1019 PTCs, in 6 (2.6%) of 235 hereditary
MTCs, and in 20 (4.1%) of 492 sporadic MTCs (159). The
rate of simultaneousMTC and PTC (3.6%) in the 727German
patients with sporadic and hereditary MTC was much lower
than that found in comparable studies from Italy (13.8% of
196 patients) and Korea (19% of 53 patients) (160,161). The
reasons for the discrepancies are unknown but may be due to
environmental conditions or differences in the study popula-
tions. Rarely, the MTC and the follicular component metas-
tasize together as histologically separate tumors in the same
target organ (162). Surgery is the primary treatment for pa-
tients with MTC mixed with follicular elements. The physi-
cian should consider treatment with radioactive iodine (RAI)
in the rare situation in which the mixed components or the
follicular element alone spreads to lymph nodes or distant
sites (163,164).
In hereditary MTC the entity CCH precedes the develop-
ment of MTC and is best demonstrated by IHC staining with
Ctn antibodies (165). CCH is actually a misnomer. Con-
sidering its multicentricity, the entity most likely represents
clonal proliferation of multiple transformed progenitor C-
cells. Therefore, terms such as C-cell carcinoma in situ or
C-cell neoplasia are more appropriate. The criteria for the
diagnosis of CCH are controversial; however, most pathol-
ogists agree that a diagnosis is warranted if there are more
than seven C-cells per cluster, complete follicles surrounded
by C-cells, and distribution of C-cells beyond the normal
anatomical location (166). C-cells are normally restricted to
the junction of the upper third and lower two-thirds of the
lateral lobes; extension beyond this region is considered in-
dicative of an abnormal C-cell proliferation. Atypical C-cell
proliferation that breaches the basement membrane or in-
vades the surrounding stroma has the potential to metastasize.
Also, the presence of a desmoplastic stromal response indi-
cates an invasive lesion. Patients with presumed sporadic
MTC who have CCH or multifocal hyperplasia on morpho-
logical examination of the entire gland, should be evaluated
for the presence of RET germline mutations. The CCH that
occurs secondarily in association with hyperparathyroidism,
chronic lymphocytic thyroiditis, renal insufficiency, and ag-
ing is not a premalignant condition (167–170).
The distinction of CCH from microcarcinoma (MTC < 1
cm and without capsular invasion) is challenging but clini-
cally significant. In a study of 776 patients with MTC, 223
(30%) of whom had microcarcinomas, increasing tumor size
(from < 2mm to 9–10mm) was associated with an increasing
incidence of lymph node metastases in patients with heredi-
tary MTC (from 6% to 62%; cure rates from 96% to 71%),
compared to patients with sporadic MTC (13% to 43%; cure
rates from 85% to 77%). Considering all cases of medullary
thyroid microcarcinoma, however, the incidence of distant
metastases was only 1.3% (171).
& RECOMMENDATION 16
The assessment of a thyroid tumor with any feature sug-
gestive of MTC should include IHC analysis to deter-
mine the presence of markers such as Ctn, chromogranin,
and CEA and the absence of thyroglobulin. Grade B Re-
commendation
& RECOMMENDATION 17
Complete notation of the features of every MTC should
follow the synoptic reporting guidelines of the College of
American Pathologists Protocol for the Examination of
Specimens from Patients with Carcinomas of the Thyroid
Gland. Grade B Recommendation
& RECOMMENDATION 18
In patients with MTC, morphological examination of the
entire gland is recommended to determine the presence of
CCH or multifocal neoplasia. Grade C Recommendation
[H] THE DIAGNOSIS OF MTC IN PATIENTS
PRESENTING WITH A THYROID NODULE
[H-1] Fine-needle aspiration biopsy (Figure 1)
Fine-needle aspiration (FNA) biopsy of thyroid nodules is
a useful and safe tool in the diagnosis of thyroid pathology.
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Medullary carcinoma has a variable appearance on aspiration
cytology. The MTC cells are usually discohesive or weakly
cohesive and may be spindle-shaped, plasmacytoid, or epi-
thelioid. Epithelioid tumors can mimic thyroid follicular
lesions, plasmacytoid tumors can be misdiagnosed as plas-
macytomas, and pure spindle cell tumors can be mistaken for
sarcomas. There may also be bizarre giant cells, oncocytic
cells, clear cells, and cells with a small cell carcinoma–like
appearance. The tumor cells may contain azurophilic peri-
nuclear cytoplasmic granules. The eccentric nuclei exhibit
chromatin granularity as a ‘‘salt and pepper’’ appearance that
is typical of neuroendocrine tumors. Amyloid can be mis-
taken for colloid and on its own is not diagnostic since it may
also be present in systemic amyloidosis, amyloid goiter or
follicular lesions (172). The diagnosis ofMTC can be verified
by immunolocalization of Ctn, chromogranin, or CEA; by
confirming lack of thyroglobulin staining; and most impor-
tantly by detecting elevated serum Ctn levels in the patient.
To investigate pitfalls in the diagnosis of MTC by FNA,
cytomorphology was reviewed in the histological slides of
34 patients with MTC. The diagnosis of MTC was correct in
28 cases; however, six cases were misdiagnosed: three as
a follicular neoplasm, one as a desmoid tumor, and two as
tumors suspicious for MTC. With no benign findings, FNA
indicated the need for surgery in all 34 patients (173). Si-
milarly, in a study of 91 cases, FNA findings were diagnostic
of MTC in 89% of cases and indicated the need for surgery in
99% (174). The most important cytological criteria of MTC
were a dispersed cell pattern of polygonal or triangular cells,
azurophilic cytoplasmic granules, and eccentrically placed
nuclei with coarse granular chromatin and amyloid (174).
Although in a meta-analysis of 15 publications, the accuracy
of FNA in diagnosing MTC in patients with MTC nodules
was less than 50%, IHC analysis of the FNA specimen and
measurement of Ctn in the FNA aspirate were performed
rarely (175). The diagnostic accuracy of FNA analysis has
been reported to be markedly increased by IHC analysis of
the FNA specimen and additionally bymeasuring Ctn levels in
the FNA washout fluid (176). Therefore, FNA should be per-
formed on thyroid nodules that are greater than 1 cm in size,
depending on the ultrasound characteristics.When histological
analysis is inconclusive or shows features suggestive of MTC,
FIG. 1. Management of patients with a thyroid nodule and histological diagnosis of medullary thyroid carcinoma. ADX,
adrenalectomy; Ctn, calcitonin; CEA, carcinoembryonic antigen; EBRT, external beam radiotherapy; FNA, fine-needle
aspiration; HPTH, hyperparathyroidism; LND, lymph node dissection; MTC, medullary thyroid carcinoma; M, metastatic
MTC; PHEO, pheochromocytoma; RET, REarranged during Transfection; TKI, tyrosine kinase inhibitor; TTX, total thy-
roidectomy; US, ultrasound.
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Ctn levels should be measured in the FNA washout fluid, and
the specimen should be evaluated by IHC staining to deter-
mine the presence of markers such as Ctn, chromogranin, and
CEA and the absence of thyroglobulin.
& RECOMMENDATION 19
Thyroid nodules that are 1 cm or greater in size should be
evaluated by FNA depending on the ultrasound character-
istics. FNA findings that are inconclusive or suggestive of
MTC should have calcitonin measured in the FNA washout
fluid and IHC staining of the FNA sample to detect the
presence of markers such as Ctn, chromogranin, and CEA
and the absence of thyroglobulin. Grade BRecommendation.
[H-2] Measurement of the serum Ctn in patients
with nodular thyroid disease level
In a recent study investigators measured serum Ctn levels
in 10,864 patients with nodular thyroid disease and detected
MTC in 0.40% (177). In this and other studies, serum Ctn
measurements had a higher diagnostic sensitivity and speci-
ficity compared with FNA findings (177–179). In the largest
study of patients diagnosed by Ctn screening, compared to an
unmatched historical control group with no Ctn screening,
the MTC was present at an earlier disease stage and post-
operative serum Ctn levels were more often undetectable.
Also, at the end of the follow-up period, complete remission
was observed in 59% of the Ctn-screened group and in 2.7%
of the control group ( p = 0.0001) (177).
In another study of patients with thyroid nodules, basal
serum Ctn measurements were less than 10 pg/mL in 5535
(95.2%) of 5817 patients (179). The remaining 282 patients,
216 with basal Ctn levels between 10 and 20 pg/mL were
followed with yearly Ctn measurements. One of the 216
patients had a thyroidectomy when the basal Ctn level rose to
33 pg/mL 2 years after initial testing and CCH was present at
thyroidectomy. Of the remaining 66 patients who had basal
serum Ctn levels above 20pg/mL, nine had basal Ctn levels
above 100 pg/mL, and at thyroidectomy, MTC was confirmed
histologically in each of them. The remaining 57 patients had
pentagastrin stimulation testing, which was positive (exceeded
100 pg/mL) in four of eight patients with basal Ctn levels
between 50 and 100 pg/mL (the thyroidectomy specimen
showed MTC in two and CCH in two), and in 8 of 49 patients
with basal Ctn levels between 20 and 50pg/mL (the thyroid-
ectomy specimen showed MTC in four and CCH in four).
The low rate of cure once disease spreads beyond the thyroid
gland supports the role of Ctn screening in the early diagnosis
of MTC in patients with thyroid nodules. However, given that
MTC is present in only 0.3%–1.4% of patients with thyroid
nodules, routine serum Ctn measurement in this population has
raised concerns of cost-effectiveness, especially when many of
the operated patients would have no MTC based on imperfect
specificity if a cutoff was chosen that optimized sensitivity.
Additionally, the clinical significance and natural history of
MTC diagnosed by Ctn screening is unknown. Although, this
practice is the standard of care at selected centers in European
countries there has been controversy regarding its acceptance in
the United States (180,181). Even though recent studies show
that Ctn measurement of thyroid nodule FNA washings may
significantly improve the sensitivity of the test, questions of cost-
effectiveness are likely to remain (176,182,183).
Concern exists that previous studies of serum Ctn levels
in patients with thyroid nodules are potentially biased be-
cause the results of subjects prospectively accrued are
compared to results of historical controls. There are no
prospective randomized trials evaluating the efficacy of
serum Ctn screening to standard evaluation of patients with
nodular goiters. Also, none of the cited studies address the
issues of morbidity and potential complications associated
with thyroidectomy in patients with abnormal serum Ctn
levels who ultimately prove to have no MTC. Does the
earlier diagnosis of MTC in a very small number of patients
with nodular goiters justify a total thyroidectomy with its
attendant complications in the larger pool of individuals
who have noMTC? The recommendations of the Task Force
regarding the use of serum Ctn screening in patients with
nodular goiters were mixed and primarily based on the
member’s country of origin.
& RECOMMENDATION 20
Realizing that opinions of experts vary regarding the use-
fulness of measuring serum Ctn levels in patients with nod-
ular goiters, the Task Force recommends that physicians
decide whether the technique is useful in the management of
patients in their clinic. Grade I Recommendation
[I] MANAGEMENT OF PATIENTS WITH A THYROID
NODULE AND HISTOLOGICAL DOCUMENTATION
OF MTC (FIGURE 1)
[I-1] Preoperative imaging studies
Patients who present with a newly detected thyroid nodule
and histological confirmation of MTC should have a physical
examination and direct DNA analysis of blood cells to detect
the presence of a RET germline mutation. If hereditary MTC
is evident, PHEOs and HPTH should be excluded. The
presence of bilateral MTC does not necessarily ensure that
the tumor is hereditary since the frequency of disease in both
thyroid lobes ranges from 0% to 9% in patients with sporadic
MTC who have no RET germline mutations (184–186).
In a study of 300 patients evaluated prior to thyroidectomy
for MTC, no distant metastases were detected when the
baseline serum Ctn level was less than 500 pg/mL (187).
However, regardless of a patient’s serum Ctn level, preop-
erative systemic imaging is indicated when there is extensive
neck disease, or signs or symptoms of distant metastases.
Ultrasound (US) evaluation of the neck is the most im-
portant preoperative imaging study in patients with thyroid
cancer. If metastatic MTC is expected preoperatively,
additional imaging procedures are indicated. Computed
tomography (CT) is the most sensitive imaging procedure
to detect lung and mediastinal lymph node metastases.
Three-phase contrast-enhanced multi-detector liver CT and
contrast enhanced magnetic resonance imaging (MRI) are
the most sensitive methods to detect liver metastases. Axial
MRI and bone scintigraphy are complementary and the
most sensitive procedures to detect bone metastases (188).
2-[18F]-fluoro-2-deoxy-D-glucose (FDG) positron emission
tomography/CT (FDG-PET/CT) and 18F-dihydroxyphenyl-
alanine F-DOPA-PET/CT are less sensitive in detecting
metastases, compared to other imaging procedures (188).
Unfortunately, no single procedure provides optimal whole-
body imaging.
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& RECOMMENDATION 21
Patients presenting with a thyroid nodule and a cytological
or histological diagnosis of MTC should have a physical
examination, determination of serum levels of Ctn and
CEA, and genetic testing for aRET germlinemutation. The
presence of a PHEO and HPTH should be excluded in
patients with hereditary MTC. Grade B Recommendation
& RECOMMENDATION 22
Ultrasound examination of the neck should be performed in
all patientswithMTC.Contrast-enhancedCTof the neck and
chest, three-phase contrast-enhanced multi-detector liver
CT, or contrast-enhanced MRI of the liver, and axial MRI
and bone scintigraphy are recommended in patients with
extensive neck disease and signs or symptoms of regional or
distant metastases, and in all patients with a serum Ctn level
greater than 500 pg/mL. Grade C Recommendation
& RECOMMENDATION 23
Neither FDG-PET/CT nor F-DOPA-PET/CT is re-
commended to detect the presence of distant metastases.
Grade E Recommendation
[I-2] The initial surgical treatment of patients
with MTC
Total thyroidectomy and dissection of cervical lymph node
compartments, depending on serum Ctn levels and US find-
ings, is standard treatment for patients with sporadic or he-
reditary MTC. Patients with a palpable thyroid nodule have a
high rate of lymph node metastases that often elude detection
preoperatively or even intraoperatively. In one study lymph
node metastases were detected in 27 (75%) of 36 patients with
MTC during total thyroidectomy and central and lateral
compartment neck dissections (189). Similarly, in another
study lymph node metastases were found in greater than 75%
of 73 patients with MTC treated by total thyroidectomy and
immediate or delayed central and bilateral functional neck
dissection (190). Patients with unilateral intrathyroidal tumors
had lymph node metastases in 81% of central compartment
(level VI) dissections, 81% of ipsilateral lateral compartment
(levels II to V) dissections, and 44% of contralateral lateral
compartment (levels II to V) dissections. In patients with bi-
lateral intrathyroidal tumors, nodal metastases were present in
78% of central compartment dissections, 71% of lateral
compartment dissections ipsilateral to the largest intrathyroid
tumor, and 49% of lateral compartment dissections contralat-
eral to the largest thyroid tumor. Surprisingly, the frequency of
lymph node metastases in the central and ipsilateral com-
partments ranged from 50% to 75%, whether the primary
tumor was less than 1 cm or greater than 4 cm. The sensitivity
of the surgeon’s intraoperative assessment of nodal metastases
was 64%, and the specificity was 71% (190).
The pattern of lymph node metastases, as demonstrated for
PTC,may also apply toMTCdependingon the size and location
of the primary tumor. Tumors located in the upper thyroid pole
metastasize first to the upper portion of the ipsilateral lateral
compartment, whereas tumors in the middle and lower portions
of the gland spread first to the central compartment (191). Tu-
mors in the upper pole of the gland, involving the lateral
compartment nodes on the ipsilateral side, skip the central
compartment in approximately 25% of cases (192). Apart from
the location of the primary intrathyroidal tumor, the overall
incidence of lateral compartment lymph node metastases is
related to the frequency of central compartment lymph node
metastases. In a study of 195 patients with MTC the rate of
ipsilateral lateral compartment lymph node metastases was
10.1%, 77%, or 98%,when no central compartment lymphnode
metastases were present, when one to three central compart-
ment lymph node metastases were present, or when four or
more central compartment lymph node metastases were pres-
ent, respectively. The rate of contralateral lateral compartment
lymph nodemetastaseswas4.9%, 38%, or 77%whenno central
compartment lymphnodemetastaseswere present, when one to
nine central compartment lymph nodemetastases were present,
or when 10 or more central compartment lymph node metas-
tases were present, respectively (193). With ipsilateral lym-
phatic drainage of tumor cells (i.e., involvement of only the
central and lateral cervical lymph node compartments on the
side of the primary neoplasm), surgical cure may be attainable
in some patients, whereas metastases in the contralateral lateral
compartment herald incurable disease (194).
The preoperative basal serum Ctn level is also useful in de-
termining the extent of lymph nodemetastases. In a study of 300
consecutive patients with MTC treated by total thyroidectomy
and compartment-oriented lymph node dissections, there was
virtually no risk of lymph nodemetastaseswhen the preoperative
serum Ctn level was less than 20pg/mL (normal reference
range<10pg/mL) (187). Basal serum Ctn levels exceeding 20,
50, 200, and 500pg/mL were associated, respectively, with
metastases to lymph nodes in the ipsilateral central and ipsilat-
eral lateral neck, the contralateral central neck, the contralateral
lateral neck, and the upper mediastinum. Bilateral compartment-
oriented neck dissection achieved postoperative biochemical
cure in at least half of the patients with pretreatment basal Ctn
levels of 1000pg/mL or less, but not in patients with levels
greater than 10,000pg/mL (187). Thus, although imperfect, the
determination of basal serum Ctn levels provides useful infor-
mation for the operative management of patients with MTC. It
should be noted that patients whose basal serum calcitonin level
is normal (<10 pg/mL) following attempted complete lymph
node dissection are said to be ‘‘biochemically cured’’ and have a
97.7% survival at 10 years (37). However, 3% of patients with a
normal baseline serum Ctn level following thyroidectomy will
have a biochemical recurrence within 7.5 years (195).
Important information can be gained also from preopera-
tive serumCEA levels. In a study of 150 patients, 54 of whom
had preoperative serum CEA levels greater than 4.7 ng/mL,
there was a respective significant association between suc-
cessive increases of serum CEA (4.7–10, 10.1–30, 30.1–
100 ng/mL, and > 100ng/mL) and the presence of 10 or more
positive cervical lymph nodes; 0%, 9%, 53%, and 69%
[p< 0.001]), involvement of cervical lymph node compartments
(central: 33%, 36%, 73%, and 93% [p=0.002]; lateral [ipsilat-
eral]: 20%, 27%, 67%, and 88% [p=0.001]; lateral [contralat-
eral]: 22%, 10%, 36%, and 73% [p=0.008]), the presence of
distant metastasis (0%, 27%, 13%, and 75% [p<0.001]), and
postoperative normalization of serum Ctn levels (biochemical
cure) (58%, 33%, 7%, and 0% [p= 0.001]) (196).
Considering the complications associated with repeat neck
operations, the surgeon should dissect the necessary lymph
node compartments during the initial thyroidectomy, based
on the frequency and pattern of lymph node metastases rel-
ative to the location and size of the primary MTC, US
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findings, and serum levels of Ctn and CEA. Clearance of
lymph nodes in the lateral neck is not without complications,
primarily lymphatic leakage, occurring in 0.5%–8%of patients,
and damage to a spinal accessory nerve with resulting shoulder
dysfunction, occurring in 25%–50% of patients (197–199).
There are two schools of thought regarding the use of
preoperative studies in the management of lymph node
compartments at thyroidectomy. Some endocrinologists and
surgeons consider preoperative US of primary importance in
detecting lymph node metastases and do not advocate com-
partment dissection if US of the neck is negative. Others
argue that elective dissection of US-normal ipsilateral central
and ipsilateral lateral neck compartments is indicated in pa-
tients with basal serum Ctn levels above 20 pg/mL. Also,
elective dissection of an US-normal contralateral lateral neck
compartment is indicated when the basal serum Ctn level is
greater than 200 pg/mL (187).
& RECOMMENDATION 24
Patients with MTC and no evidence of neck lymph node
metastases by US examination and no evidence of distant
metastases should have a total thyroidectomy and dissec-
tion of the lymph nodes in the central compartment (level
VI). Grade B Recommendation
& RECOMMENDATION 25
In patients with MTC and no evidence of neck metastases on
US, andnodistantmetastases, dissectionof lymphnodes in the
lateral compartments (levels II–V) may be considered based
on serum Ctn levels. The Task Force did not achieve con-
sensus on this recommendation. Grade I Recommendation
& RECOMMENDATION 26
Patients with MTC confined to the neck and cervical lymph
nodes should have a total thyroidectomy, dissection of the
central lymph node compartment (level VI), and dissection
of the involved lateral neck compartments (levels II–V).
When preoperative imaging is positive in the ipsilateral
lateral neck compartment but negative in the contralateral
neck compartment, contralateral neck dissection should be
considered if the basal serum calcitonin level is greater than
200 pg/mL. Grade C Recommendation
[J] RESULTS OF THYROIDECTOMY IN PATIENTS
WITH MTC
Unfortunately, most patients withMTC and regional lymph
node metastases have systemic disease and are not cured by
total thyroidectomy and bilateral neck dissection (200,201).
In a study of 534 patients with MTC treated by total thy-
roidectomy and neck dissection, both decreased lymph node
yield and an increased ratio of metastatic lymph nodes to the
total number of lymph nodes resected appeared to be associ-
ated with poor survival (202). In another study metastases to
10 or more lymph nodes or involvement of more than two
lymph node compartments precluded normalization of serum
Ctn (203). Quantitative assessment of lymph node metastases,
1–10 (N1), 11–20 (N2), and more than 20 (N3), is an im-
portant prognostic classifier that should be incorporated into
the AJCC staging systems, which currently includes N1a and
NIb categories referring only to qualitative involvement of
lymph node compartments (Table 5) (204).
Table 5. American Joint Committee on Cancer
TNM Classification (Thyroid Cancer)
Description
Primary tumor (T)a
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor 2 cm or less in greatest
dimension, limited to the thyroid
T1a Tumor 1 cm or less, limited to the thyroid
T1b Tumor more than 1 cm, but not more than
2 cm, in greatest dimension, limited to
the thyroid
T2 Tumor more than 2 cm, but not more
than 4 cm, in greatest dimension,
limited to the thyroid
T3 Tumor more than 4 cm in greatest dimension
limited to the thyroid, or any tumor with
minimal extrathyroid extension
(e.g., extension to sternothyroid muscle
or perithyroid soft tissues)
T4a Moderately advanced disease; tumor of any
size extending beyond the thyroid capsule
to invade subcutaneous soft tissues,
larynx, trachea, esophagus, or recurrent
laryngeal nerve
T4b Very advanced disease; tumor invades
prevertebral fascia or encases carotid
artery or mediastinal vessels
Regional lymph nodes (N)b
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
N1a Metastasis to level VI (pretracheal,
paratracheal, and prelaryngeal/Delphian
lymph nodes)
N1b Metastasis to unilateral, bilateral, or
contralateral cervical (levels I, II, III,
IV, or V) or retropharyngeal
or superior mediastinal lymph nodes
(level VII)
Distant metastases (M)
M0 No distant metastasis
M1 Distant metastasis
Anatomic stage/prognostic groups
Stage I T1, N0, M0
Stage II T2, N0, M0
T3, N0, M0
Stage III T1, N1a, M0
T2, N1a, M0
T3, N1a, M0
Stage IVA T4a, N0, M0
T4a, N1a,M0
T1, N1b, M0
T2, N1b, M0
T3, N1b, M0
T4a, N1b, M0
Stage IVB T4b, any N, M0
Stage IVC Any T, any N, M1
Modified from the 7th Edition of the American Joint Committee
on Cancer Staging Manual, with permission of Springer-Verlag
New York, Inc., 175 Fifth Avenue, New York, NY 10010, USA.
aAll categories may be subdivided: (s) solitary tumor and (m)
multifocal tumor (the largest determines the classification).
bRegional lymph nodes are the central compartment and the
lateral cervical and upper mediastinal lymph node compartments.
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Despite the inability to cure all patients with regional lymph
nodemetastases, the resection of local metastasesmay decrease
the risk of local recurrence. Also, the clearance of central and
lateral compartments may prevent future complications such as
invasion of recurrent laryngeal nerves, the aerodigestive tract,
or lateral neck nerves with respective loss of speech, altered
swallowing, and arm or shoulder dysfunction (205,206). For
these reasons, most surgeons recommend a compartment-
oriented lymph node dissection at the primary thyroidectomy if
metastatic lymph nodes are evident (202,207).
[K] MANAGEMENT OF PATIENTS WITH LOCALLY
ADVANCED OR METASTATIC MTC
In most patients with MTC the goal is to perform a total
thyroidectomy, with or without compartment-oriented lymph
node dissections. However, in the presence of advanced
disease the goals of surgery are more palliative with attention
to minimizing complications. In the presence of MTC that
invades the trachea, thyroid cartilage, or esophagus, the ex-
tent of extirpative surgery (palliative debulking, laryngectomy,
esophagectomy, or laryngopharyngectomy) is determined by an
assessment of the ability tomaintain speech and swallowing and
the patient’s life expectancy based on the extent of disease and
other medical comorbidities. These decisions are best made on
an individualized basis by an experienced multidisciplinary
medical team, including the patient.
& RECOMMENDATION 27
In the presence of extensive regional or metastatic disease
less aggressive surgery in the central and lateral neck may
be appropriate to preserve speech, swallowing, parathy-
roid function, and shoulder mobility. External beam ra-
diotherapy (EBRT), systemic medical therapy, and other
nonsurgical therapies should be considered to achieve
local tumor control. Grade C Recommendation
[L] MANAGEMENT OF PATIENTS FOLLOWING
AN INCOMPLETE THYROIDECTOMY AND LYMPH
NODE DISSECTION
Occasionally, the diagnosis of MTC is made following a
unilateral hemithyroidectomy. The opposite thyroid lobe
should be removed in patients with hereditary MTC because
the likelihood thatMTC is already present or will develop in the
future approaches 100%. In patients with sporadic MTC the
incidence of bilateral MTC ranges from 0% to 9%, and there
are few studies evaluating patient management in this setting
(187,188). In a prospective study of 15 patients treated by
hemithyroidectomy for sporadic MTC, 12 (80%) achieved a
biochemical cure as defined by a postoperative serumCtn level
within the normal range following calcium and pentagastrin
stimulation. Metastases to regional nodes and large tumor size
were adversely related to biochemical cure (186).
Completion thyroidectomy following hemithyroidectomy
is not indicated unless the patient has a RET germline mu-
tation, a significant elevation of basal or stimulated serumCtn
levels postoperatively, or imaging studies showing residual
MTC. For simplicity, serum Ctn levels above the upper
normal value of the reference range may be a reasonable level
at which completion thyroidectomy should be recommended.
However, there are no data on which to base this recommen-
dation, and the decision to follow a patient with sporadic MTC
after hemithyroidectomy without further surgery should be
made on an individual basis, weighing the potential risks and
benefits of additional surgery compared to watchful waiting.
During follow-up, a progressive increase in the basal serumCtn
level above 150pg/mL should prompt additional imaging.
Patients with residual lymph node metastases after thy-
roidectomy are likely to benefit from re-operation. In a study
of 334 patients a repeat operation was performed for persis-
tent MTC, as evidenced by elevated serum Ctn levels
(1797 pg/mL [885–2736 pg/mL]), (208). Systematic central
and lateral lymph node dissection attained biochemical cure
in 59 (44%) of 133 patients who had no metastases in lymph
nodes removed at prior surgery. Conversely, biochemical
cure was attained in only 12 (18%) of 65 patients in whom
one to five metastatic lymph nodes had been removed pre-
viously (208). If more than five metastatic lymph nodes were
resected at prior surgery the biochemical cure rate fell to 5%
(2 of 43 patients). When preoperative basal serum Ctn levels
exceeded 1000 pg/mL (reference range < 10 pg/mL) bio-
chemical cure was exceptional (1 of 76 patients). It is note-
worthy that 18% of the 334 patients were referred with
unilateral permanent recurrent laryngeal nerve palsy, pre-
senting a challenge in the dissection of the contralateral neck
(208). Recently, surgeons have used continuous intraoperative
nerve monitoring during thyroidectomy for primary or recur-
rentMTC. The technique signals impending nerve injury, most
often due to traction on the nerve, and allows timely corrective
action (209). However, there have been no multicenter, pro-
spective, randomized trials comparing this technique to thy-
roidectomy alone. These data suggest that systematic lymph
node dissection in patients who had an inadequate lympha-
denectomy at initial thyroidectomy is worthwhile, as long as
the preoperative serum Ctn level is less than 1000pg/mL and
five or fewer metastatic lymph nodes were resected initially.
Beyond these thresholds, the focus of surgical treatment shifts
to the maintenance of local control in the neck.
& RECOMMENDATION 28
Following unilateral thyroidectomy for presumed sporadic
MTC completion thyroidectomy is recommended in pa-
tients with a RET germline mutation, an elevated post-
operative serum Ctn level, or imaging studies indicating
residual MTC. The presence of an enlarged lymph node in
association with a normal serum Ctn level is not an indi-
cation for repeat surgery. Grade B Recommendation
& RECOMMENDATION 29
In patients having an inadequate lymph node dissection at the
initial thyroidectomy a repeat operation, including compart-
ment oriented lymph node dissection, should be considered if
the preoperative basal serum CTN level is less than 1000pg/
mL and five or fewer metastatic lymph nodes were removed
at the initial surgery. Grade C Recommendation
[M] MANAGEMENT OF NORMAL PARATHYROID
GLANDS RESECTED OR DEVASCULARIZED
DURING SURGERY
The surgeon should be experienced in identifying parathyroid
glands and have expertise with parathyroid autotransplantation.
Normal parathyroid glands can be accidentally removed or
devascularized during thyroidectomy or central neck lymph
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node dissection. Whenever possible, viable parathyroid tissue
should be left in situ on a vascular pedicle. If the blood supply to
a parathyroid gland cannot be preserved during thyroidectomy,
or if the status of the blood supply is questionable or clearly
inadequate, parathyroid tissue should be grafted to the sterno-
cleidomastoid muscle in patients with sporadic MTC and
MEN2B and in patientswithMEN2Awho have aRETmutation
rarely associated with HPTH. Otherwise, the parathyroid tissue
should be grafted to a heterotopic muscle bed, such as the bra-
cheoradialis, where portions of the graft can be removed if graft-
dependent hyperparathyroidism develops (210).
& RECOMMENDATION 30
During a total thyroidectomy forMTC, normal parathyroid
glands should be preserved in situ on a vascular pedicle. If
all normal parathyroid glands are resected or if none ap-
pear viable at the termination of the procedure, slivers of a
parathyroid gland should be transplanted into the sterno-
cleidomastoid muscle in patients with sporadic MTC,
MEN2B, or MEN2A and a RETmutation rarely associated
with HPTH. In patients with MEN2A and a RET mutation
associated with a high incidence of HPTH, the parathyroid
tissue should be transplanted in a heterotopic muscle bed.
Grade B Recommendation
[N] HORMONE REPLACEMENT
FOLLOWING THYROIDECTOMY
Following thyroidectomy there is no reason to suppress
thyrotropin (TSH) since the MTC is not a follicular neo-
plasm; however, replacement L-thyroxine is needed to
maintain serum TSH levels in the euthyroid range. Also,
patients need to be monitored for hypocalcemia, which is
almost always transient; however, treatment with oral cal-
cium and calcitriol is indicated if patients become symp-
tomatic or have persistently prolonged hypocalcemia.
Withdrawal of replacement therapy is guided by serial mea-
surements of serum calcium.
& RECOMMENDATION 31
Serum TSH should be measured within 4–6 weeks postop-
eratively. Replacement therapy with levothyroxine should
be administered with the goal of maintaining serum TSH
levels in the euthyroid range. Grade B Recommendation
& RECOMMENDATION 32
Serum calcium levels should be monitored postoperatively.
Oral calcium and vitamin D should be administered to
patients who develop symptomatic hypocalcemia. Chronic
replacement therapy is indicated in patients who cannot be
weaned from medication. Grade B Recommendation
[O] PROPHYLACTIC THYROIDECTOMY
IN CHILDREN WITH HEREDITARY MTC (FIGURE 2)
Prophylactic surgery is most applicable for patients with
hereditary cancer syndromes and ideally should meet the
following criteria: 1) the genetic mutation causing the ma-
lignancy is characterized by complete or near complete
penetrance; 2) there is a highly reliable test for detecting the
mutation; 3) the organ at risk is expendable, or if not ex-
pendable, there is therapy to replace the function of the organ;
4) the precancerous organ can be removed with minimal
morbidity and virtually no mortality; and 5) there is a reliable
test to determine if the operation has been curative. Many
hereditary cancer syndromes meet some, but not all of these
criteria, whereas MEN2A and MEN2B meet each of them. In
patients with hereditary MTC, there is a classic progression
FIG. 2. Management of patients with a RET germline mutation detected on genetic screening. ATA, American Thyroid
Association risk categories for aggressive medullary thyroid carcinoma (MTC) (HST, highest risk, H, high risk, MOD,
moderate risk); Ctn, calcitonin; CEA, carcinoembryonic antigen; HPTH, hyperparathyroidism; PHEO, pheochromocytoma;
RET, REarranged during Transfection; TTX, total thyroidectomy; US, ultrasound.
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from CCH, to MTC, to loco-regional lymph nodes, and ul-
timately to distant sites, a process that occurs from months to
years and largely depends on the RET mutation (64,211). In
this setting it is possible to remove the thyroid before it be-
comes cancerous, or if cancer has developed it is confined
to the gland.
The term ‘‘prophylactic thyroidectomy’’ has been used to
describe early removal of the thyroid gland in children who
have inherited a mutated RET allele; however, in most cases
CCH or frank MTC is already present at the time of thy-
roidectomy. In the present context we use the term ‘‘pro-
phylactic’’ to define removal of the thyroid before MTC
develops or while it is clinically unapparent and confined to
the gland. Timely thyroidectomy for MTC favorably alters
the associated morbidity and mortality, thus, the question is
not whether prophylactic thyroidectomy should be performed
in patients with hereditary MTC, but at what age.
Prior to the introduction of direct DNA analysis to detect a
mutatedRET allele the diagnosis of hereditaryMTCwas based
on determination of the serum Ctn level. Although a C-cell
disorder could be detected at an early age with biochemical
testing, there were no generally accepted criteria specifying the
serum Ctn level at which thyroidectomy should be performed.
Expectedly, some children were subjected to thyroidectomy
based on the serum Ctn level only to learn years later on direct
DNA analysis that they had not inherited a RET mutation
(64,212,213). With the discovery that mutations in the RET
oncogene cause theMEN2 syndromes and the recognition that
there is a correlation between genotype and phenotype, the
focus on early diagnosis shifted to direct DNA analysis. It soon
became apparent, however, that there was great heterogeneity
in the age of onset and aggressiveness ofMTC, not only among
different families with the same RET mutation (excepting
mutations in RET codon 634 and codon 918), but within in-
dividual families having the same RET mutation.
Given our evolving understanding of hereditary MTC, the
decision regarding the age of prophylactic thyroidectomy is
no longer based on direct DNA analysis alone, rather it is
driven by additional clinical data, the most important being
the basal or stimulated serum Ctn level (214). Given the lack
of generally accepted guidelines relating specific basal or
stimulated serum Ctn levels to the development of a C-cell
disorder it is important that clinicians become familiar with
the reference range of the Ctn assay in their medical center
and establish criteria for recommending thyroidectomy in
children known to have inherited a mutated RET allele. The
management plan for a child with hereditary MTC should be
communicated to and understood by the parents.
Compared to adults, children, and especially infants, have
higher complication rates associated with thyroidectomy, the
most significant being hypoparathyroidism. The parathyroid
glands are often hard to identify in very young children because
they are small, translucent, and difficult to distinguish from
surrounding tissues. Even though complications are signifi-
cantly minimized when experienced surgeons perform the
thyroidectomy (215,216), one might consider delaying the
procedure in children less than 2 years of age. Also, some
pediatricians have concern that potential detrimental effects of
insufficient thyroid hormone replacement, perhaps due to
noncompliance, have attendant consequences in young chil-
dren, such as impaired brain development and retarded growth
(217).
Nevertheless, there are significant risks in delaying surgery
in family members who have inherited a mutated RET allele,
and regardless of the patient’s age, one must balance the risks
of thyroidectomy against the possibility that the MTC will
not be cured if thyroidectomy is delayed. This conundrum is
exemplified by a family with MEN2A and the RET codon
L790F mutation. Of 22 family members 15 had a RET codon
L790F mutation and 8 of the 15 had elevated basal or stim-
ulated serum Ctn levels. Five patients (45–76 years of age)
with elevated serum Ctn levels and clinical stage pT1N0M0
disease were cured biochemically following thyroidectomy
and lymph node dissection. The three remaining patients with
elevated serum Ctn levels refused surgery. Seven patients
with serum Ctn levels less than 30 pg/mL did not have sur-
gery and were followed expectantly. The follow-up ( < 5
years) in the seven patients was complicated, because three of
them considered it impractical to continue periodic evalua-
tions, or for other reasons chose not to do so (218). This is a
significant risk factor for clinicians and their patients who
choose to base the timing of thyroidectomy on long-term
periodic physical examinations and measurement of serum
Ctn levels. In time, patients may tire of repeat evaluations and
discontinue periodic clinic visits, only to be seen again,
perhaps years later, with clinically evident disease.
[O-1] Prophylactic thyroidectomy for children
with MEN2A (Figure 2)
Children with MEN2A and RET codon 634 mutations
(ATA-H category) often develop MTC during the first years
of life; therefore, annual physical examination, cervical US,
and measurement of serum Ctn levels should begin at 3 years
of age (219). Children in the ATA-MOD category, compared
to children in the ATA-H category, typically develop a less
aggressive MTC at a later age. The behavior of the tumor can
be variable, however, as evidenced by a child with a RET
codon 804 mutation who died of metastatic MTC at 12 years
of age (219–221). Although much can be learned from
studying several families with the same RET mutation, there
may be substantial variability among families not only in the
age of onset and the aggressiveness of the MTC, but in the
clinical expression of the disease spectrum. For example, in
studies of various families with the RET codon C609S mu-
tation the development of CCH or MTC ranged from 9 to 48
years of age, and with the exception of one family, the mean
age of MTC onset was 20 years. Also, in some families with
the RET codon C609S mutation no one developed a PHEO,
while in other families not only were there PHEOs, but in one
kindred PHEOwas the dominant endocrinopathy, there being
no clinically evident MTC (222–225). Considering the clin-
ical variability of disease expression in family members in
the ATA-MOD category, annual physical examination, cer-
vical US, and measurement of serum Ctn levels, should begin
at 5 years of age.
Several international groups have reported their experi-
ence with prophylactic thyroidectomy in children with
MEN2A (217,226–233). In one series of 46 children, five
(9.2%) children, all over 13 years of age (with RETmutations
in codons 620, 630, 634, 634, and 634), had persistent or
recurrent MTC following prophylactic thyroidectomy (217).
In another series 50 children were evaluated 5 or more years
after total thyroidectomy and central zone neck dissection by
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measurement of serum Ctn levels following stimulation with
combined calcium and pentagastrin. There was no persistent
or recurrent MTC in 44 (88%) children (one with lymph node
metastases). The remaining six children, ages 8, 10, 11, 14,
16, and 19 years (with RET mutations in codons 618, 618,
620, 620, 634, and 634) developed persistent or recurrent
MTC postoperatively, as indicated by a detectable basal or
stimulated serum Ctn level. Two of the six children had
lymph node metastases (227).
The MTC that occurs in young children with MEN2A is
often small and in one study there were no lymph node me-
tastases or evidence of residual MTC when the basal Ctn was
less than 30 pg/mL preoperatively or when the primary tumor
was smaller than 10mm (234). In other studies there were no
lymph node metastases at thyroidectomy if the basal preop-
erative serum Ctn level was below 40pg/mL (234–236). In an
additional two studies lymph node metastases were uncom-
mon before 11 years of age (227,237). Thus, when the pre-
operative basal serum Ctn is less than 40pg/mL, a total
thyroidectomy without central (level VI) neck dissection is
adequate therapy. Such a strategy should reduce the risk of
damage to the parathyroid glands and the laryngeal nerves.
Ultimately, almost all patients with MEN2A require thy-
roidectomy. Children in the ATA-H category should have a
thyroidectomy at or before 5 years of age, with the timing and
extent of surgery guided by serum Ctn levels. Children in the
ATA-MOD category should have a thyroidectomy in child-
hood or young adulthood, the timing depending primarily on
serum Ctn levels. It is important that the pediatrician and
surgeon caring for the child collaborate with the child’s parents
to plan the time for thyroidectomy. Some parents may wish to
proceed with thyroidectomy during childhood rather than opt
for long-term evaluation, which might last for decades.
[O-2] Prophylactic thyroidectomy for children
with MEN2B (Figure 2)
In patients with MEN2B and a RET codon M918T muta-
tion (ATA-HST category), the MTC is usually highly ag-
gressive and if possible thyroidectomy should be performed
early in life. Two groups of patients with MEN2B should be
considered separately: the 25% or fewer who have known
hereditary MEN2B and the 75% or more who have de novo
RET mutations and phenotypically normal parents.
In children with hereditary MEN2B, macroscopic MTC
and nodal metastases may occur during the first year of life
(238). For these reasons, genetic testing should be done soon
after birth in at-risk infants. Children who have inherited
MEN2B should have a thyroidectomy in the first year of life,
perhaps even in the first months of life, the exact timing
determined by the surgeon and pediatrician in consultation
with the child’s parents (238,239). There are complicating
factors in infants. Serum Ctn levels are extremely high in the
first months of life and of limited value in timing thyroidec-
tomy. More importantly, the parathyroid glands can be very
difficult to identify intraoperatively, creating an inordinate risk
of hypoparathyroidism. In the absence of suspicious lymph
nodes, the decision to perform a central neck dissection should
be based on whether the parathyroid glands are identified and
can either be preserved in situ or autotransplanted. The surgeon
should consider foregoing a central neck dissection if he
cannot identify the parathyroid glands.
In children with de novo RET codon M918T mutations the
diagnosis of MEN2B is usually made upon detection of a
thyroid nodule (240,241). In one study of 21 patients with de
novoMEN2B and a RET codonM918Tmutation the mean age
at diagnosis was 14.2 years (range 1–31 years). In 18 of the 21
patients the mean preoperative basal serum Ctn level was
26,080 pg/mL (range 35–105,000pg/mL), and in 4 (18%) of
the 21 patients serum Ctn levels were within the normal range
postoperatively (242). Despite the aggressiveness of MTC in
MEN2B, some children are cured by thyroidectomy (243,244).
It is critically important that physicians be aware of the char-
acteristic phenotype associatedwithMEN2B, since it is almost
always evident prior to the detection of a thyroid nodule or a
PHEO. In a study of 44 children with MEN2B, three patients
with hereditary disease had a thyroidectomy during the first
year of life and were cured (243). Of the 41 patients with de
novo RET mutations, 12 were diagnosed upon recognition of
nonendocrine manifestations of MEN2B: ganglioneuro-
matosis (n= 6), oral symptoms (n= 5), ocular manifestations
(n= 4), and skeletal abnormalities (n= 1). The remaining
29 patients were diagnosed because of symptomatic MTC
(n= 28) or PHEO (n= 1). The patients detected because of
nonendocrine manifestations, compared to those with symp-
tomatic MTC or PHEO, were significantly younger (5.3 vs.
17.6 years of age; p< 0.001), and also had lower preoperative
serumCtn levels (mean 115 vs. 25,519pg/mL), tumors smaller
than 10mm (67% vs. 0%), a lower incidence of extrathyroidal
extension (0% vs. 81%), fewer lymph node metastases (42%
vs. 100%), and a lower incidence of distant metastases (8% vs.
79%). Most importantly, they were more often cured bio-
chemically following thyroidectomy (58% vs. 0%). All nine
children having thyroidectomy prior to age 4 years were cured
biochemically, compared to only 1 of 35 children having
thyroidectomy after age 5 years (244).
Theoretically, very young children with MEN2B could be
monitored and thyroidectomy delayed until they are older and
the operation is less risky. There have been no studies evaluating
the efficacy of such an approach. While central neck dissection
may be foregone in very young children with MEN2B, such is
not the case in older children with a palpable MTC and elevated
serum Ctn levels, since they are at high risk for lymph node
metastases and the benefits of central neck dissection outweigh
the potential risks associated with the procedure.
In patients with MEN2B who have RET A883F codon
mutations, or double mutations involving RET codon V804M
and either RET codon Y806C, S904C, E805K, or Q781R, the
MTC appears to be less aggressive compared to the MTC in
patients withMEN2B and the RET codonM918Tmutation. It
is difficult to establish management guidelines in these two
groups, however, since their mutations are rare and only
small numbers of patients have been evaluated.
& RECOMMENDATION 33
Experienced physicians and surgeons in tertiary care cen-
ters should be responsible for the management of children
with MEN2A or MEN2B. Grade B Recommendation
& RECOMMENDATION 34
Children in the ATA-HST category with a RET codon
M918T mutation should have a thyroidectomy in the first
year of life, perhaps even in the first months of life. In the
absence of suspicious lymph nodes the performance of a
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central neck dissection should be based on whether the
parathyroid glands can be identified and left in situ or au-
totransplanted. The surgeon and pediatrician caring for the
patient, in consultation with the child’s parents, should de-
cide the timing of thyroidectomy. GradeCRecommendation
& RECOMMENDATION 35
Children in the ATA-H category should have a thyroid-
ectomy performed at age 5 years, or earlier based on the
detection of elevated serum Ctn levels. A central neck
dissection should be performed in children with serum Ctn
levels above 40 pg/mL, or with evidence on imaging or
direct observation of lymph node metastases. The surgeon
and pediatrician caring for the patient, in consultation with
the child’s parents, should decide the timing of thyroid-
ectomy. Grade B Recommendation
& RECOMMENDATION 36
Children in the ATA-MOD category should have a physical
examination, US of the neck, andmeasurement of serumCtn
levels beginning around 5 years of age. The timing of thy-
roidectomy should be based on the detection of an elevated
serum Ctn level; however, 6-month or annual evaluations
may extend to several years or decades. Parents who are
concerned about a long-term evaluation programmay opt to
have their child’s thyroid gland removed around 5 years of
age. The surgeon and pediatrician caring for the patient, in
consultation with the child’s parents, should decide the
timing of thyroidectomy. Grade B Recommendation
[P] MANAGEMENT OF PHEO IN PATIENTS
WITH MEN2A AND MEN2B
PHEOs usually present in the third or fourth decade of life
in patients with MEN2A and the diagnosis is usually made
concurrently with or following the diagnosis of MTC. An
undiagnosed PHEO in a patient undergoing a thyroidectomy
may result in substantial morbidity and even death. Thus, in
patients with hereditary MTC, it is critical to exclude the
presence of a PHEO prior to thyroidectomy by measuring free
plasma or fractionated urinary metanephrines, or both. Either
CT or MRI can confirm the location of a PHEO. If both MTC
and a PHEO are present in a patient, the PHEO should almost
always be removed first. In patients who present with MTC,
and it is unknown whether it is sporadic or familial, a PHEO
should be excluded prior to thyroidectomy if determination of
the RET status takes an inordinate amount of time. A PHEO
should also be excluded in patients with MEN2 who wish to
become pregnant. A PHEOdiagnosed during pregnancy should
be resected prior to the third trimester if possible.
Following bilateral adrenalectomy there is a significant
risk of adrenal insufficiency, thus unilateral adrenalectomy is
indicated in patients with a solitary PHEO, even though the
majority of themwill develop a contralateral PHEOwithin 10
years (63,245). Bilateral PHEOs should be resected with
corticosteroid coverage intraoperatively and postoperatively.
Postoperative surveillance is critical in patients with no ad-
renal glands and they must carry information on themselves
regarding the necessity of glucocorticoid treatment should
they become acutely ill or injured.
Laparoscopic adrenalectomy or retroperitoneoscopic ad-
renalectomy is the procedure of choice for the treatment
of unilateral or bilateral PHEOs (246). There appears to be
no outcome difference between laparoscopic and retro-
peritoneoscopic approaches in synchronous bilateral adrenal
surgery (247,248). Realizing the risk of Addison crises in
patients without adrenocortical tissue, some surgeons have
focused on subtotal adrenalectomy (249). Subtotal adrenalec-
tomy that preserves 10%–15% of residual adrenal cortical tis-
sue appears to offer adrenal stress capacity sufficient to obviate
the need for corticosteroid supplementation in more than 80%
of patients (250). The risk of recurrent PHEO, however, is 20%
within 20 years after subtotal adrenalectomy (251).
PHEOs may develop as early as 8 and 12 years of age,
respectively, in children in the ATA-H and ATA-HST cate-
gories, and as early as 19 years of age in children in the ATA-
MOD category (252–255). In three studies of patients with
MEN2, the mean ages at presentation of PHEOs were 25
years (range, 18–40 years), 25.5 years (range, 19–31 years),
and 32.4 years (range, 15–41 years), respectively (256–258).
The recommended time to begin screening for a PHEO is
based on data from the literature including an analysis of 474
patients with hereditary MTC, 84 (17.8%) of whom devel-
oped PHEOs, and 20 (4.2%) of whom developed HPTH
(257). Screening for PHEO in children in the ATA-HST,
ATA-H, and ATA-MOD categories should begin at 11, 11,
and 16 years of age, respectively.
& RECOMMENDATION 37
Screening for PHEO should begin by age 11 years for
children in the ATA-H and ATA-HST categories and by
age 16 years in children in the ATA-MOD category.
Screening consists of measuring free plasma metane-
phrines and normetanephrines or 24-hour urinary meta-
nephrines and normetanephrines. Adrenal imaging with
CT or MRI is indicated in patients with positive bio-
chemical results. Grade C Recommendation
& RECOMMENDATION 38
Patients with MEN2A or MEN2B and a histological di-
agnosis of MTC regardless of age and presenting symp-
toms must have a PHEO excluded prior to any
interventional procedure. The presence of a PHEOmust be
excluded in women with MEN2A or MEN2B who are
planning a pregnancy or are pregnant. If a PHEO is de-
tected it should be treated preferably prior to the third
trimester. Grade C Recommendation
& RECOMMENDATION 39
If they coexist, a PHEO should be removed prior to surgery
for either MTC or HPTH. Grade B Recommendation
& RECOMMENDATION 40
After appropriate preoperative preparation a PHEO should
be resected by laparoscopic or retroperitoneoscopic adre-
nalectomy. Subtotal adrenalectomy to preserve adrenal
cortical function should be considered as an alternative
procedure. Grade B Recommendation
& RECOMMENDATION 41
Patients with no adrenal glands require glucocorticoid and
mineralocorticoid replacement therapy and should be
carefully monitored to ensure that their steroid levels are
adequate. Patients should be educated regarding the risk of
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adrenal crisis and wear a bracelet or a necklace indicating
that they have no adrenal glands and are on corticosteroid
replacement therapy. Glucocorticoid supplementation will
be required if they become severely ill or are injured.
Grade B Recommendation
[Q] MANAGEMENT OF HPTH IN PATIENTS WITH MEN2A
Surveillance for HPTH should include albumin-corrected
calcium or ionized serum calcium measurements (with or
without serum intact-PTH levels) beginning at age 11 years
in patients in the ATA-H category and at age 16 years in
patients in the ATA-MOD category. In a study of 188 pa-
tients with MEN2A (ATA-H category), 36 had HPTH (259).
The mean age at diagnosis of HPTH was 33.7 years (range
12–70 years); however, HPTH has been reported in children
in the ATA-H category as early as 2, 6, 7, and 10 years of age
(259–262). The HPTH primarily occurs in patients with
exon 11 RET codon mutations, most often in those with RET
codon 634 mutations, and less frequently in patients with
exon 10 RET codon mutations. As more families with
MEN2A have been studied, it has become apparent that
their HPTH, in contrast to that occurring in families with
MEN1, is mild and often asymptomatic (263,264). Enlarged
parathyroid glands are occasionally found at the time of
thyroidectomy for MTC in patients who are normocalcemic
preoperatively (261,262).
Treatment options for patients with HPTH and no prior
neck surgery include: 1) subtotal parathyroidectomy leaving
one gland or a piece of one gland in situ; 2) total parathy-
roidectomy with autotransplantation of small slivers of para-
thyroid tissue to a heterotopic site; or 3) resection of only
enlarged glands, with intraoperative parathyroid hormone
(PTH) monitoring, to document complete removal of hyper-
functioning parathyroid tissue (265). As the surgical man-
agement of patients with MEN2A and HPTH has evolved,
option 3 has become the preferred procedure (264,265). The
management of HPTH in children is similar to that in adults;
however, because of the rarity of the disease in youngsters
there are little data on long-term outcomes.
A more difficult situation arises when HPTH develops
subsequent to thyroidectomy. In this setting preoperative
localization (with sestamibi scanning, US, or CT) should
precede repeat neck exploration. Enlarged parathyroids
should be excised with PTH monitoring; however, it may be
difficult to identify all parathyroid glands, since some may be
masked by scarring or were removed at prior thyroidectomy.
If a single large parathyroid gland and one or more normal
size parathyroid glands are found, the enlarged parathyroid
should be resected, and parathyroid function monitored by
PTH immunoassay. If PTH levels are normal the operation
can be terminated. If, however, there is evidence of persistent
HPTH, the search for enlarged parathyroids should continue.
If a single large parathyroid gland is identified and the
status of the remaining parathyroids is unknown, the large
gland should be resected and parathyroid function monitored
by PTH immunoassay. If there is evidence of normal para-
thyroid function the operation can be terminated. If there is
no evidence of function a portion of the removed parathyroid
should be grafted to a heteropic site.
If one enlarged parathyroid gland is identified and there is
histological documentation that three glands have been re-
moved previously, either a portion of the gland should be left
in situ on a vascular pedicle, or the gland should be resected
and slivers of it grafted to a heterotopic site. Alternatively,
the gland could be resected and a portion cryopreserved
for subsequent autografting. Currently, cryopreservation is
practiced infrequently at a few medical centers (266). If the
patient remains hyperparathyroid despite one or more re-
operations, or the patient is not a candidate for parathyroid-
ectomy, medical therapy with calcimimetics should be
considered (267,268).
& RECOMMENDATION 42
Patients in the ATA-H and ATA-MOD categories should
be screened for HPTH at the time of screening for PHEO
(by age 11 years in patients in the ATA-H category and by
age 16 years in patients in the ATA-MOD category). Grade
C Recommendation
& RECOMMENDATION 43
In patients with HPTH only visibly enlarged parathyroid
glands should be resected. If all four glands are enlarged
surgical options include subtotal parathyroidectomy with a
piece of one gland left in situ on a vascular pedicle or total
parathyroidectomy with a heterotopic autograft. Grade C
Recommendation
& RECOMMENDATION 44
Patients who develop HPTH subsequent to thyroidectomy
for MTC should have localization studies performed prior
to repeat neck surgery. At reoperation all enlarged para-
thyroid glands should be removed, and parathyroids of
normal size should be left in situ. If only one enlarged
parathyroid gland is identified and there is histological
documentation that three parathyroid glands have been
removed previously, a portion of the enlarged gland should
either be left in situ with an adequate blood supply or
grafted to a heterotopic site. Grade C Recommendation
[R] EVALUATION OF PATIENTS FOLLOWING
THYROIDECTOMY (FIGURE 3)
Postoperative staging is used to separate low-risk from
high-risk patients with MTC. The AJCC staging system has
been applied to patients with MTC (Table 5). The TNM sys-
tem utilizes tumor size, extrathyroidal invasion, nodal meta-
stasis, and distant spread of cancer. However, in patients with
MTC the TNM classification lacks important prognostic fac-
tors such as gradations of age and postoperative serum Ctn
levels. Also, the AJCC TNM classifications for MTC catego-
rize lymph nodemetastases not by number but according to the
location of nodes within (N1a) or without (N1b) the central
neck, regardless of the number of lymph node metastases or
involved compartments. The Task Force felt that the AJCC
staging system should be modified to include four groups of
lymph node metastases: 0, 1–10, 11–20, and > 20 (200,204).
It is important to evaluate patients in the postoperative
period to determine if thyroidectomy has been curative. In a
study of 124 patients having total thyroidectomy for tumors
other than MTC, 121 (97%) had no serum Ctn detectable by
ICMA. In those with detectable Ctn levels, there was either
residual thyroid tissue or ectopic secretion of Ctn from a
nonthyroid malignancy (269). These data indicate that
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postoperative serum Ctn levels should be undetectable fol-
lowing complete removal of thyroid tissue. In the same study
32 of 68 patients with MTC treated by total thyroidectomy
had undetectable basal and stimulated serum Ctn levels
postoperatively and appeared cured. Of the remaining 36
patients, 22 had pathologically increased basal serum Ctn
levels and in 11 of them residual MTC tissue was identified
postoperatively. Progressive increases in serum Ctn in the
other 11 patients indicated tumor recurrence. Of the re-
maining 14 patients, nine had undetectable basal serum Ctn
levels; however, in two patients serum Ctn levels increased to
a pathological range with stimulation. The remaining five
patients had measureable serum Ctn within the normal range,
but in three patients there was a pathological increase in
serum Ctn with stimulation. In 2 of the 14 patients there was
evidence of recurrent MTC; however, there was no clinical or
imaging evidence of recurrent disease in 12 of the 14 patients.
Because of the short length of evaluation after thyroidec-
tomy, it was impossible to determine the frequency with
which metastatic MTC developed in the various groups of
patients (269).
The normalization of serum Ctn levels postoperatively is
associated with a favorable outcome; however, there has been
controversy regarding how long it takes for the serum Ctn
level to reach its nadir. Some clinical investigators have
proposed that 3 months postoperatively is the optimal time to
determine the nadir of serum Ctn levels (270,271). Due to its
prolonged half-life, serum levels of CEA may take even
longer to reach a nadir. Some investigators consider a basal or
stimulated serum Ctn level at or below the limits of the ICMA
indicative of a curative thyroidectomy for MTC (272). Others
propose that a thyroidectomy is curative if the postoperative
stimulated serum Ctn level is less than 10 pg/mL (271,273).
Using this latter criterion, 453 of 1430 patients in the Groupe
d’Etude des Tumeurs a` Calcitonine database treated by total
thyroidectomy with or without lymph node dissection were
considered to have residual disease at their last evaluation.
Fifteen (3.7%) of these patients met the criteria for recurrence
because they had been considered cured (basal and penta-
gastrin stimulated serum Ctn less than 10 pg/ML) 6 months
after surgery (195).
In a study of 63 consecutive patients treated by total thy-
roidectomy for MTC, the postoperative basal serum Ctn level
was less than 10 pg/mL in 35 patients and their 3- and 5-year
relapse-free survival rates were 94% and 90%, respectively,
as opposed to 78% and 61% in patients with basal Ctn levels
above 10 pg/mL (272). In patients with basal serum Ctn
levels less than 150 pg/mL following thyroidectomy, persis-
tent or recurrent disease is almost always confined to lymph
nodes in the neck (272).
Detection of persistent or recurrent MTC should begin
with neck US. In a study of 212 patients with various his-
tological types of thyroid carcinoma additional sites of
metastatic disease were detected by US but not physical ex-
amination in 21 (20%) of 107 patients prior to primary thy-
roidectomy, in 9 (32%) of 28 patients with persistent disease
FIG. 3. Management of patients following thyroidectomy for persistent or recurrent medullary thyroid carcinoma. Ctn,
calcitonin; CEA, carcinoembryonic antigen; EBRT, external beam radiotherapy; MTC, medullary thyroid carcinoma; TFTs,
thyroid function tests; TSH, thyrotropin; TKI, tyrosine kinase inhibitor; TTX, total thyroidectomy; US, ultrasound.
REVISED ATA MANAGEMENT GUIDELINES FOR MTC 589
after thyroidectomy, and in 52 (68%) of 77 patients with
recurrent disease after thyroidectomy. The numbers for 61
patients withMTCwere, respectively, 6 (27%) of 22 patients,
7 (70%) of 10 patients, and 17 (59%) of 29 patients (274).
FNA biopsy is useful in confirming the diagnosis of meta-
static MTC, and measurement of Ctn levels in the FNA
washout fluid may increase the specificity and sensitivity of
the procedure (182,183).
Imaging techniques to detect persistent or recurrent MTC
include neck and chest CT, three-phase contrast-enhanced
CT, contrast-enhanced MRI, and US of the liver, bone scin-
tigraphy, MRI of the spine and pelvis, PET, and FDG-PET/
CT, and F-DOPA-PET/CT (188,275–280). The sensitivity of
these tests in localizing metastatic disease ranges between
50% and 80%, but it is likely to be significantly lower in the
setting of modestly elevated serum Ctn values (277,278).
In one study imaging procedures were performed in 55
consecutive patients with MTC and elevated serum levels of
Ctn (median 1250 pg/mL) and CEA (median 37 ng/mL).
Neck recurrences were demonstrated in 50 patients by US
(56%), CT (42%), and FDG-PET/CT (32%). Lung and me-
diastinal lymph node metastases were demonstrated in 55
patients by CT (35% and 31%, respectively) and by FDG-
PET/CT (15% and 20%, respectively). Liver metastases were
demonstrated in 41 patients by MRI (49%), CT (41%), US
(41%), and FDG-PET/CT (27%). Bone metastases were
demonstrated in 55 patients by FDG-PET/CT (35%), bone
scintigraphy (40%), and MRI (40%). Bone scintigraphy
was complementary with MRI for axial skeletal lesions but
superior to MRI for the detection of peripheral bone lesions.
The authors concluded that the most efficient imaging pro-
cedures for detecting MTC at various sites were US (neck),
CT (chest), MRI (liver), and MRI and bone scintigraphy
(axial skeleton) (188). Imaging with anti-CEA antibodies and
scintigraphy with various tracers, such as somatostatin ana-
logs, metaiodobenzylguanidine (MIBG), dimercaptosuccinic
acid, and gastrin, are usually of low sensitivity (281–286).
In subsequent studies, however, FDGPET/CT and F-DOPA
PET/CT proved superior to conventional imaging procedures
in detecting metastases in patients with MTC (287–291). F-
DOPA PET/CT had a higher sensitivity, compared to FDG-
PET/CT, and seemed more important in assessing extent of
disease. On the other hand, FDG-PET/CT correlated signifi-
cantly with progressive disease. Survival was significantly
lower in FDG-PET/CT-positive patients compared to FDG-
PET/CT-negative patients, and although the same was true for
F-DOPA PET/CT-positive patients compared to those who
were negative, the survival in patients with a positive FDG-
PET/CT was lower and independent of the F-DOPA-PET/CT
result. Therefore, the two studies are complementary with F-
DOPA PET/CT having a higher sensitivity in detecting tumor
load, and FDG-PET/CT more accurately identifying patients
with progressive disease (290,291). However, these imaging
techniques with PET are expensive and selection criteria and a
medico-economic evaluation are required before being used
routinely in clinical practice.
& RECOMMENDATION 45
Clinicians should consider TNM classification, the number
of lymph node metastases, and postoperative serum Ctn
levels in predicting outcome and planning long-term
follow-up of patients treated by thyroidectomy for MTC.
Grade C recommendation
& RECOMMENDATION 46
Serum levels of Ctn and CEA, should be measured
3 months postoperatively, and if undetectable or within
the normal range, they should be measured every 6
months for 1 year, and then yearly thereafter. Grade C
Recommendation
& RECOMMENDATION 47
Patients with elevated postoperative serum Ctn levels less
than 150 pg/mL should have a physical examination and
US of the neck. If these studies are negative the patients
should be followed with physical examinations, mea-
surement of serum levels of Ctn and CEA, and US every 6
months. Grade C Recommendation
& RECOMMENDATION 48
If the postoperative serum Ctn level exceeds 150 pg/mL
patients should be evaluated by imaging procedures, in-
cluding neck US, chest CT, contrast-enhanced MRI or
three-phase contrast-enhanced CT of the liver, and bone
scintigraphy and MRI of the pelvis and axial skeleton.
Grade C Recommendation
[R-1] Measurement of doubling times of serum Ctn
and CEA to determine rate of progression of MTC
One can estimate the growth rate of MTC from sequential
imaging studies using response evaluation criteria in solid tu-
mors (RECIST) that document incremental increases in tumor
size over time (292). One can also determine the MTC growth
rate by measuring serum levels of Ctn or CEA over multiple
time points to determine the rate at which each marker’s value
doubles (293–296). In a retrospective study of 65 patients
treated by total thyroidectomy and bilateral lymph node dis-
section and then evaluated from 2.9 to 29.5 years after surgery,
the 5- and 10-year survival rates in those with serum Ctn dou-
bling times less than 6 months were 25% and 8%, respectively,
compared to 92% and 37% respectively in those with doubling
times between 6 and 24 months (293). All patients with Ctn
doubling times greater than 24 months were alive at the end of
the study. The TNM stage, the European Organization for Re-
search and Treatment of Cancer score, and Ctn doubling time
were significant predictors of survival by univariate analysis, but
only the Ctn doubling time was an independent predictor of
survival by multivariate analysis. The Ctn doubling time was a
better predictor of survival than theCEAdoubling time (293). In
another study of 55 consecutive patients withMTC the doubling
times of Ctn and CEAwere concordant in 80% of patients, such
that when both markers were 25 months or less (16 of 17 pa-
tients) or 25 months or greater (12 of 14 patients), progressive
disease was evident in 94% and 14%, respectively (294). When
the doubling times were discordant (nine patients) and either the
Ctn doubling time or the CEA doubling time was 25 months or
less, progressive disease was observed in five patients. The
clinician should determine the doubling times of both markers
(294). To calculate the doubling time of a tumor marker single
exponentials are fitted to the tumor marker concentration by
nonlinear least square regression.
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Reliable estimates are obtained using at least four data
points over a minimum of 2 years; however, doubling times
less than 6 months can be reliably estimated within the first
12 months postoperatively (293). The ATA provides a cal-
culator to determine doubling times of serial serum Ctn and
CEA measurements (www.thyroid.org/thyroid-physicians-
professionals/calculators/thyroid-cancer-carcinoma).
& RECOMMENDATION 49
In patients with detectable serum levels of Ctn and CEA
following thyroidectomy, the levels of the markers should
be measured at least every 6 months to determine their
doubling times. Grade B recommendation
[S] TREATMENT OF PATIENTS WITH REGIONAL
METASTATIC MTC
[S-1] Neck exploration
In a recent study of patients with MTC nodal metastases
began appearing at basal serum Ctn levels of 40 pg/mL
in patients having initial thyroidectomy and 10pg/mL in pa-
tients having reoperative surgery (reference range< 10pg/mL).
In patients with lymph node metastases at the time of re-
operation, distant metastases began appearing at preoperative
basal serumCtn levels above 150 pg/mL, exceeded 50% at Ctn
levels of 5000pg/mL, and were virtually always present when
Ctn levels exceeded 20,000pg/mL (206). In a recent study of
patients with one to two or four sites of distant metastases,
the median (and range) of serum Ctn was 1510pg/mL (21–
6000pg/mL) and 18,450pg/mL (276–247,000pg/mL), re-
spectively (294).
Patients with persistent or recurrent MTC localized to the
neck following thyroidectomy are candidates for repeat neck
operations. Several investigators have reported their experi-
ence with repeat neck surgery for persistent or recurrent re-
gional MTC; however, there has been no clinical trial where
patients have been staged and randomized to either reoperation
or observation alone. In about one third of patients treated by
repeat neck operations for persistent or recurrent MTC, the
postoperative basal or stimulated serum Ctn levels are reduced
to the ‘‘normal range’’; however, they are rarely undetectable
(297–300). Long-term outcomes in patients undergoing repeat
neck operations have been fairly good, with excellent preven-
tion of recurrence in the central neck. One group reported du-
rable reductions in serum Ctn levels (297).
& RECOMMENDATION 50
Surgical resection of persistent or recurrent loco-regional
MTC in patients without distant metastases should include
compartmental dissection of image-positive or biopsy-
positive disease in the central (level VI) or lateral (levels
II–V) neck compartments. Limited operative procedures,
such as resection of only grossly metastatic lymph nodes,
should be avoided unless there has been prior extensive
surgery in a compartment. Grade C Recommendation
[S-2] Role of postoperative radioiodine ablation
Clinical investigators considered the possibility that RAI
uptake in follicular cells might damage adjacent MTC cells
by way of a ‘‘bystander effect’’ (301,302). However, in a
recent study of 293 patients treated by total thyroidectomy for
MTC, there was no difference in disease-specific survival in
61 patients who received postoperative RAI compared to 232
who did not. The authors concluded that RAI is not indicated
following thyroidectomy for MTC (303). However, RAI
should be considered in the rare patient whose regional or
distant metastases contain MTC mixed with either PTC or
FTC (163,164).
& RECOMMENDATION 51
Postoperative RAI is not indicated following thyroidec-
tomy for MTC; however, it should be considered in pa-
tients whose regional or distant metastases contain MTC
mixed with either PTC or FTC. Grade E Recommendation
[S-3] Adjunctive EBRT to the neck
The benefits of EBRT adjuvant to thyroidectomy in pa-
tients with MTC are difficult to evaluate because there have
been no prospective trials in which patients have been ran-
domized to EBRT compared to observation alone (304–310).
Generally, EBRT has been reserved for selected patients with
a high likelihood of tumor recurrence following thyroidec-
tomy, as determined by the operating surgeon and the radi-
ation oncologist.
In a study of 51 patients with MTC who received adjuvant
EBRT in doses ranging from 60 to 65 Gy, the only significant
variable for loco-regional recurrence-free survival on multi-
variate analysis was postoperative residual disease status
(p= 0.0005). The 5-year rate of local control was 100% in those
without residual disease, 65% in those with microscopic resid-
ual disease, and 24% in those with gross residual disease (305).
One of the largest studies of MTC involved 73 patients treated
by total or near total thyroidectomy. Extraglandular extension
was present in 56% of patients and 74% of patients had lymph
node metastases. Patients were treated with EBRT (n= 46)
ranging from 20 to 75.5 Gy (median 40 Gy) or were observed
(n= 27). Comparing treated to untreated patients, there was no
difference in local or regional relapse-free rates (309).
In an analysis of the SEER data from 1998 to 2004, adjuvant
EBRT showed no overall survival benefit in patients withMTC
and positive lymph nodes (306). The intent of postoperative
EBRT in patients withMTC, however, has not been to improve
survival, but to achieve local control in those at high risk of
regional recurrence. Several studies suggest that EBRT is ef-
fective in this regard. For example 34 patients at high risk for
MTC recurrence following thyroidectomy were treated with a
median total radiation dose of 60 Gy with conformal tech-
niques. The 5-year loco-regional relapse-free survival rate was
87% and the disease-specific and overall survival rates were
62% and 56%, respectively (307). In a recent study of 17 pa-
tients treated with adjuvant EBRT with a total dose of 60.8 Gy,
none of six patients who received adjuvant therapy developed
recurrence in the radiated field. Five patients developed loco-
regional recurrence and were treated with a total dose of 59.4
Gy and a durable response was seen in three patients. The
authors concluded that adjuvant EBRT might be effective in
preventing loco-regional recurrence in selected patients (310).
Acute toxicity of EBRT includes skin erythema and des-
quamation, mucositis, esophagitis, and laryngeal edema. Due
to odynophagia and dysphagia, some patients require a per-
cutaneous gastrostomy (PEG) tube for nutrition. In most
patients, the PEG tube is removed when acute toxicity has
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resolved, usually within 2–3 months after completion of
EBRT. Late toxicities include skin hyperpigmentation, telan-
giectasia, hoarseness, osteoradionecrosis, trismus, arterial in-
jury, and brain or central nerve injury (311). Xerostomia may
also occur following EBRT although the parotid glands are
better spared with the use of intensity-modulated radiation
therapy (IMRT). Long-term esophageal stricture requiring
dilatation or nutritional support or tracheal stenosis may also
occur but are rare. Scarring and fibrosis occurring after EBRT
may complicate subsequent surgery. Despite the potential
acute and late toxicities, EBRT is fairly well tolerated (311).
Loco-regional control is a valid endpoint in patients with
MTC, as progression in the cervical region can have a sig-
nificant impact on quality of life. Adjuvant EBRT should be
considered in patients with incompletely resected MTC or
those at high risk for local recurrence; however, the potential
benefits must be weighed against the probable acute and
chronic toxicity associated with the therapy. Prior to initiat-
ing EBRT, surgeons should be sure that patients are not
candidates for a repeat operation because the procedure will
be more difficult technically following EBRT and will be
associated with significant complications.
The typical postoperative dose, 60–66 Gy, delivered to the
thyroid bed over 6 weeks using 4–6 MV photons, should
eradicate microscopic disease. Gross residual disease should
be treated to 70 Gy or higher for effective local control. Based
on CT findings, IMRT should be used to treat MTC adjacent
to the spinal cord. Dosimetric studies have demonstrated that
dose escalation to the thyroid bed can be accomplished using
IMRT while simultaneously sparing normal tissues. Imaging
with CT, MRI, and PET ensures accurate target volume de-
lineation, which must encompass the thyroid bed including
the central compartment. The ipsilateral and contralateral
compartments may also be encompassed within the target at
the discretion of the radiation oncologist.
& RECOMMENDATION 52
Postoperative adjuvant EBRT to the neck and mediastinum
should be considered in patients at high risk for local re-
currence (microscopic or macroscopic residual MTC, ex-
trathyroidal extension, or extensive lymph node metastases),
and those at risk of airway obstruction. The potential benefits
must be weighed against the acute and chronic toxicity as-
sociated with the therapy. Grade C Recommendation.
[T] EVALUATION OF PATIENTS WITH DISTANT
METASTASES (FIGURE 3)
All patients with cancer, especially those in whom cancer
is incurable, benefit from psychological support. Even though
the presence of a somatic RET codon M918T mutation in a
patient’s tumor or rapid doubling times of serum Ctn and
CEA levels are useful prognostic indicators, it is best to do
nothing in asymptomatic patients with no detectable meta-
stases. Once metastases appear, the clinician must decide
which patients require therapy, balancing the often slow rate
of tumor progression associated with a good quality of life,
against the limited efficacy and potential toxicities of local
and systemic therapies. Considering that metastatic MTC is
incurable, the management goals are to provide loco-regional
disease control, palliate symptoms of hormonal excess (such
as diarrhea or Cushing’s syndrome), palliate symptomatic
metastases (such as pain or bone fracture), and control me-
tastases that threaten life (such as bronchial obstruction or
spinal cord compression).
[T-1] Role of open or laparoscopic evaluation
of the liver and selective venous catheterization
with measurement of hepatic and peripheral vein
stimulated Ctn levels
Standard imaging procedures often fail to detect MTC
metastases in patients with elevated serum Ctn levels fol-
lowing thyroidectomy. Techniques such as laparoscopic
or open evaluation of the liver or sampling of the venous
effluent of solid organs to detect elevated Ctn levels could
document the presence of occult metastases. Patients shown
to have distant metastases would not be candidates for ex-
tensive loco-regional surgery with curative intent. In 41
patients with elevated serum Ctn levels following thyroid-
ectomy for MTC various localization procedures were per-
formed: CT or MRI (n= 37), laparoscopic (n = 36) or open
(n = 5) visual examination and biopsy of the liver, and se-
lective venous catheterization, with measurement of hepatic
and peripheral vein stimulated Ctn levels (n = 17) (312). Only
laparoscopic or open evaluation and biopsy of the liver
proved useful in the identification of occult metastatic dis-
ease. Liver metastases, identified in 8 (19.5%) of 41 patients
by laparoscopic (n = 7) or open evaluation, appeared as small
white nodules less than 5mm in size (312). CT scans iden-
tified metastatic disease in only one of the eight patients. Of
17 patients evaluated by hepatic vein sampling, 10 had he-
patic vein/peripheral vein serum Ctn ratios greater than 1.3;
however, only two of them had metastases confirmed by
laparoscopy. Most asymptomatic patients with elevated
serum Ctn levels and occult metastatic disease are not sur-
gical candidates because natural history studies indicate that
many of them have a relatively good prognosis, especially if
the Ctn and CEA doubling times exceed 2 years (313–315).
& RECOMMENDATION 53
Systemic therapy should not be administered to patients
who have increasing serum Ctn and CEA levels but
no documented metastatic disease. Nor should systemic
therapy be administered to patients with stable low-volume
metastatic disease, as determined by imaging studies and
serum Ctn and CEA doubling times greater than 2 years.
Grade C Recommendation
& RECOMMENDATION 54
In patients with persistent or recurrent MTC following
thyroidectomy, one should consider laparoscopic or open
evaluation and biopsy of the liver to exclude occult me-
tastases before subjecting them to a long and arduous re-
peat neck operation. Grade C Recommendation
[U] DIAGNOSIS AND TREATMENT OF PATIENTS
WITH CLINICALLY EVIDENT METASTATIC DISEASE
[U-1] Brain metastases
Clinically apparent brain metastases occur in 1%–5% of
patients with MTC. Bo¨rcek and associates found only 10 re-
ported cases in a literature review; however, the prevalence is
almost certainly underreported due to the infrequent use of
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central nervous system imaging in patients with advanced MTC
(316). Patients with widespread metastases and neurological
symptoms should be evaluated for the presence of brain meta-
stases. Treatment of brain metastases by surgical resection,
EBRT, or stereotaxic radiosurgerymay provide local control and
improve the quality of life; however, patients usually succumb
from progressive systemic disease within a short time after the
diagnosis of central nervous system metastases (317,318).
& RECOMMENDATION 55
Brain imaging should be performed in patients with met-
astatic MTC and neurologic symptoms, including patients
who are candidates for systemic therapy. Patients with
isolated brain metastases are candidates for surgical re-
section or EBRT (including stereotactic radiosurgery).
Whole-brain EBRT is indicated for multiple brain meta-
stasis. Grade C Recommendation
[U-2] Bone metastases
The management of patients with bone metastases includes
therapies such as vertebroplasty, surgical excision, thermo-
ablation (radiofrequency or cryoablation), cement injection,
and EBRT (319). Patients with acute symptoms from spinal
cord compression require urgent treatment with corticosteroid
administration and acute surgical stabilization (320). It is ex-
tremely uncommon for patients with bone metastases to be
rendered free of disease; however, in one study 70% of patients
treated with EBRT had significant pain reduction lasting for
months (321). Treatment with either intravenous bispho-
sphonates (zoledronic acid or pamidronate) or the receptor
activator of nuclear factor kappa-B ligand (RANKL) inhibitor,
denosumab, in patients with thyroid cancer has been effective
in relieving pain from bony metastases and in preventing or
delaying the occurrence of other skeletal related events (322).
Side effects of these potent antiresorptives include osteone-
crosis of the jaw, atypical subtrochanteric fractures, and hy-
pocalcemia (323,324). There is little experiencewith studies of
bisphosphonates in patients with MTC.
& RECOMMENDATION 56
Patients with spinal cord compression require urgent treat-
ment with glucocorticoid therapy and surgical decompres-
sion. If patients are not candidates for surgery EBRT alone
should be administered. Grade C Recommendation
& RECOMMENDATION 57
Patients with MTC who have fractures or impending
fractures require treatment. Therapeutic options include
surgery, thermoablation (radiofrequency or cryotherapy),
cement injection, and EBRT. Grade C Recommendation
& RECOMMENDATION 58
Treatment with denosumab or bisphosphonates is re-
commended for patients with painful osseous metastases.
Grade C Recommendation
[U-3] Lung and mediastinal metastases
Lung metastases are usually multiple and often associated
with mediastinal lymph node metastases. It may be necessary
to resect lung or mediastinal lesions causing local compression
of an airway or bleeding. Other therapeutic options are EBRT
or radiofrequency ablation. MTC invading the central airway
may be amenable to laser therapy, photodynamic therapy, or
airway stenting (325). Systemic therapy is indicated in patients
with widespread metastases that are progressing.
& RECOMMENDATION 59
Surgical resection should be considered in patients with
large solitary lung metastases. Radiofrequency ablation
should be considered when the metastases are peripheral
and small. Systemic therapy should be considered in pa-
tients with multiple metastases that are progressively in-
creasing in size. Grade C Recommendation
[U-4] Hepatic metastases
Liver metastases occur in 45% of patients with advanced
MTC. Treatment is indicated in patients with liver metastases
that are large, increasing in size, or associated with symptoms
such as diarrhea or pain. Single large metastases should be re-
sected if possible. Liver metastases, however, are often multiple
and disseminated throughout the parenchyma and are usually not
amenable to surgery, percutaneous ethanol ablation, or radio-
frequency ablation. In this situation the best treatment may be
either chemoembolization or systemic therapy (326–329). In one
study of chemoembolization in 12 patients withMTCmetastatic
to the liver a partial radiological response occurred in 42% and
disease stabilization occurred in 42%. Diarrhea improved in two
(40%) of five patients. Following a single cycle, the duration of
partial responses and stabilizations exceeded 16 months. The
extent of liver involvement was the main factor that influenced
results. Partial responses were observed in patients with less than
30% of the liver involved and with individual metastases less
than 30mm in size. When disease progression occurred, patients
could be offered repeat treatment,which often resulted in another
partial tumor response, usually of shorter duration (326). In an-
other study of 11 patients hepatic metastases were treated from
one to nine times by chemoembolization. Symptomatic response
was noted in all patients, but biochemical and radiological re-
sponses were noted in only six of them (328). It is important that
patients have adequate renal and hepatic function and that they
be carefully evaluated prior to treatment. One patient died during
the first course of therapy due to the presence of an unexpected
PHEO (328).
& RECOMMENDATION 60
Surgical resection should be considered in patients with
large isolated hepatic metastases. Chemoembolization
should be considered in patients with disseminated tumors
less than 30mm in size involving less than a third of the
liver. Grade C Recommendation
[U-5] Cutaneous metastases
Patients with MTC rarely develop cutaneous metastases.
Characteristically, they are erythematous, maculopapular
eruptions, or tumor nodules that develop on the upper chest,
neck, or scalp. The metastases are often located adjacent to a
scar from a previous operation, or they develop as a com-
ponent of widely metastatic disease. Percutaneous etha-
nol injection of cutaneous metastases may be useful (330).
Skin metastases respond to treatment with EBRT, but the
prognosis is poor because most patients succumb to their
disease within a year after diagnosis (330).
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& RECOMMENDATION 61
If possible cutaneous metastases should be excised surgi-
cally. Multiple cutaneous lesions are best treated by EBRT
or ethanol injection. Grade C Recommendation
[U-6] Palliation of patients with advanced MTC
Palliative surgery can be effective treatment for patients
with metastatic disease. The metastases are frequently painful
and resistant to medical treatment. Also, space-occupying
metastases that cause acute spinal cord compression, or airway
and esophageal obstruction (with coughing, dyspnea, and
difficulty swallowing) can be improved by resection of tumor,
EBRT, or the administration of systemic therapy. Tumor de-
bulking is often effective in alleviating the diarrheal syndrome
occurring in patients with advanced MTC.
& RECOMMENDATION 62
Palliative therapy, including surgery, EBRT, or systemic
therapy, should be considered in patients with metastases
causing pain, mechanical compression, or signs and
symptoms of hormonal excess. Grade C Recommendation
[V] SYSTEMIC THERAPY
Single agent or combination cytotoxic chemotherapeutic
regimens administered to patients with MTC are characterized
by low response rates (15%–20%) of short duration, although
they may be indicated in selected patients. The most effective
regimens are combination therapy with doxorubicin and an-
other agent, or 5-fluorouracil and dacarbazine (331–333).
There is limited experience with radiolabeled molecules
delivering high radiation dose to cancers. Response, survival,
and long-term safety of systemic [90Y-DOTA]-TOC were
evaluated in a phase II clinical trial of patients with advanced
MTC, increasing serum Ctn levels, and tumor uptake on 111In-
octreoscan (334). Of 31 patients, 18 (58.1%) had a post-
therapeutic prolongation of the serum Ctn doubling time of
at least 100%. Only 9 (29%) of the 31 patients, however,
experienced reduction of serum Ctn levels and were des-
ignated responders. The responders had a significantly
longer median survival from the time of treatment compared
to nonresponders, 74.5 months (range, 15.7–107 months)
compared to 10.8 months (range, 1.4–85 months; p = 0.02).
Thirteen percent of patients developed hematologic toxi-
cities, and 23% developed renal toxicities. The degree of
111In-octreoscan tumor uptake was not associated with treat-
ment response or improvement in survival (334).
The efficacy of pretargeted radio-immunotherapy with
bispecific monoclonal antibody and 131I-labeled bivalent
hapten has shown promising results in early studies of pa-
tients with advanced MTC; however, there have been no
prospective, randomized trials comparing this therapy to
other therapies or a placebo (335,336). Treatment with 131I-
MIBG is generally regarded as ineffective in patients with
MTC, although some reports have described partial tumor
remission or stability (337,338). At present treatment with
radioisotope-based therapy should only be considered in the
context of a clinical trial.
& RECOMMENDATION 63
The use of single agent or combinatorial cytotoxic chemo-
therapeutic regimens should not be administered as first-line
therapy in patients with persistent or recurrent MTC given
the low response rates and the advent of promising new
treatment options. Grade D Recommendation
& RECOMMENDATION 64
Treatment with radiolabeled molecules or pretargeted
radio-immunotherapy may be considered in selected
patients, ideally in the setting of a well-designed clinical
trial. Grade C Recommendation
[V-1] The basis for targeted therapy with TKIs
Germline RET mutations are present in virtually all pa-
tients with MEN2A and MEN2B. Approximately half of the
patients with sporadic MTC have somatic RET mutations,
and 18%–80% of patients without somatic RET mutations
have somatic RAS mutations. Also, vascular endothelial
growth factor (VEGF) receptors (VEGFR-1 [FLT-1] and
VEGFR-2 [FLK-1, KDR]) are often overexpressed in MTC,
both in tumor cells and in the supporting vascular endothe-
lium (339). Many agents that target VEGFR-2 kinase also
target RET kinase. In recent years several TKIs (axitinib,
cabozantinib, gefitinib, imatinib, motesanib, sorafenib, su-
nitinib, and vandetanib) have been evaluated in phase I, II,
and III clinical trials of patients with advanced MTC (340–
350). In phase II clinical trials partial response rates ranged
from 0% to 50%, with a large number of patients demon-
strating prolonged stable disease. On the basis of recently
completed phase III clinical trials the U.S. Food and Drug
Administration (FDA) and the European Medicines Agency
(EMA) approved two orally administered TKIs, vandetanib
(2011) and cabozantinib (2012), for the treatment of patients
with advanced progressive MTC.
[V-1-1] Clinical trials of vandetanib in patients
with advanced MTC
Aphase II clinical trial with vandetanib, targeting the RET,
EGFR, and VEGFR kinases, was evaluated at a maximal
tolerated dose (300mg/d) in 30 patients with hereditary
MTC. Partial responses were observed in 10 patients, among
whom six had a confirmed partial response, and another 16
patients had stable disease longer than 24 weeks (347). An-
other phase II trial with vandetanib (100mg/d) included 19
patients with hereditary MTC. A partial response was ob-
served in three patients and stable disease longer than 24
weeks was seen in another 10 patients. However, it was not
clear whether there was a relationship between dose and ef-
ficacy or between dose and toxicity (348).
A prospective, randomized, double blind, phase III trial
(National Clinical Trial [NCT]00322452) of 331 patients
with symptomatic or progressing locally advanced or meta-
static MTC compared PFS in patients treated with vandetanib
(300mg/d) or placebo (349). The median PFS was signifi-
cantly prolonged from 19.3 months in the placebo arm to a
predicted median of 30.5 months (median not yet reached) in
the vandetanib arm (hazard ratio [HR], 0.46; p< 0.0001).
Partial responses were observed in 45% of patients treated
with vandetanib, with a predicted median duration of re-
sponse of 22 months. The improvement in quality of life,
pain reduction, and diarrhea allowed several patients in the
vandetanib arm to resume a normal social life. All subgroups of
patients, with regard to tumor burden, progression rate, or
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symptoms, experienced significant PFS benefits from treatment.
Also, PFS benefits were observed both in patients with a RET
mutation and those without a RET mutation. In 41% of patients
the RET status was unknown due to the inability to sequence all
RET exons. Adverse events, including diarrhea, fatigue, rash and
folliculitis, photosensitization, hypertension, and prolongation of
the QTc interval, were mainly grade 1 or 2. Twelve percent of
patients receiving vandetanib discontinued treatment due to
toxicity and 35% required dose reductions because of an adverse
event (349). The FDA approved vandetanib in April 2011 with
Risk Evaluation and Mitigation Strategies (REMS), and the
EMA approved vandetanib in November 2011 for the treatment
of aggressive and symptomatic MTC in patients with un-
resectable locally advanced or metastatic disease.
However, the EMA approval was conditional, and there
was a request for the company marketing vandetanib to
provide more evidence regarding benefit in patients with and
without the RET mutation in their tumor.
[V-1-2] Clinical trials of cabozantinib in patients
with advanced MTC
A phase I/II trial with cabozantinib, targeting the kinases
of RET, c-MET, and VEGFR, included 35 evaluable MTC
patients. Seventeen patients had a partial response, and in 10
of them a partial response was confirmed (344). Partial re-
sponses were observed regardless of somatic RET mutation
status in both treatment-naı¨ve patients and in those who had
been treated previously with another kinase inhibitor, sug-
gesting the absence of cross-resistance with other com-
pounds. In a randomized, prospective phase III trial of 330
patients with progressive, metastatic, or locally advanced
MTC (NCT00704730), treatment with cabozantinib (140mg/
d) was compared to placebo (350). Median PFS was signif-
icantly improved from 4.0 months (placebo) compared to
11.2 months (cabozantininb) (HR, 0.28; p < 0.0001). Benefits
in PFS were observed in all subgroups studied. The overall
response rate was 28% (350). Side effects were signifi-
cant and included diarrhea, abdominal discomfort, fatigue,
hypertension, palmo-plantar erythrodysesthesia, and gastro-
intestinal fistulas. In fact, 16% of patients receiving cabo-
zantinib discontinued treatment due to toxicity, and 79%
required dose reductions because of an adverse event (350).
A recent analysis demonstrated benefits of cabozantinib
treatment in patients with either RET or RAS mutated tumors
(351). On the basis of the results of the phase III clinical trial,
the FDA and the EMA approved cabozantinib for the treat-
ment of patients with advanced disease.
In the two phase III trials thus far completed, vandetanib
and cabozantinib have shown the potential to provide high
rates of disease control with durable responses and a highly
significant improvement of PFS. However, the drugs have to
be given daily and chronically to maintain tumor control.
Short-term toxicity is significant, with dose reduction or
treatment withdrawal in a significant proportion of patients.
Also, there are few data on long-term toxicity and no data on
overall survival. Currently, treatment with the drugs is indi-
cated only in patients with significant tumor burden and
documented tumor progression.
Patients treated with TKIs for advanced MTC require
careful monitoring because they are at increased risk for
developing hypothyroidism, characterized by elevated serum
TSH levels despite normal serum levels of free triiodothy-
ronine and thyroxine (340). Although the mechanism for this
metabolic complication is unclear, it has recently been shown
that the TKI sorafenib induces alteration in triiodothyro-
nine and thyroxine clearance probably by inducing type 3-
deiodinase activity (352,353).
Unresolved issues include the following:
1) Should vandetanib or cabozantinib be offered as first-
line therapy? Is the FDA-approved starting dosage of
140mg/d for cabozantinib too toxic? Is a starting
dosage of 40–100mg/d more reasonable? This latter
dosage has been recommended in several clinical trials
of prostate cancer since approval of the drug for the
treatment of advanced MTC (354).
2) What are the mechanisms of resistance to the TKIs
given that with time virtually all patients will cease to
respond to the drugs?
3) Does treatment with either TKI improve overall sur-
vival? It must be noted that even when progression
occurs, many patients have a long life expectancy and
will have received several lines of treatment following
therapy with either vandetanib or cabozantinib that
may confound assessment of overall survival.
4) When should treatment with TKIs be terminated in
patients with stable disease, or in patients who have a
mixed response?
It is critical that we understand the mechanisms of resis-
tance to these TKIs because without this information it will
be impossible to develop trials of logical combinatorial
therapies, either with two TKIs or a TKI and a conventional
cytotoxic chemotherapeutic agent.
& RECOMMENDATION 65
In patients with significant tumor burden and symptomatic
or progressive metastatic disease according to RECIST
treatment with TKIs targeting both RET and VEGFR ty-
rosine kinases should be considered as systemic therapy.
The TKIs vandetanib or cabozantinib can be used as sin-
gle-agent first-line systemic therapy in patients with ad-
vanced progressive MTC. Grade A Recommendation
[W] TREATMENT OF PATIENTS WITH HORMONALLY
ACTIVE METASTASES
Diarrhea is a common occurrence in patients with ad-
vanced MTC and markedly elevated serum Ctn levels.
Rarely, the MTC cells inappropriately secrete corticotropin-
releasing hormone (CRH) or ACTH.
[W-1] Diarrhea
Diarrhea occurs most frequently in patients with advanced
disease and hepatic metastases. The diarrhea may be hy-
persecretory, due to enhanced gastrointestinal motility, or a
combination of both (355,356). The diarrhea can be debili-
tating both in terms of quality of life and nutrition. Patients
with advanced MTC and diarrhea should be advised to avoid
alcohol intake and to maintain a diet that limits high-fiber
foods. The antimotility agents loperamide, diphenoxylate/
atropine, or codeine have minimal side effects and should be
used as first-line therapy. Treatment with somatostatin ana-
logs and debulking of large tumors has also been employed.
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Reports of somatostatin analog therapy for diarrhea have
been small nonrandomized cohort studies with variable re-
sults, suggesting modestly improved symptoms in some pa-
tients (357,358). In single-center studies the combination of
somatostatin analogs with interferon-alpha has been reported
to improve symptoms of flushing and diarrhea, although
others have not confirmed these findings (359,360). Local
treatment of large hepatic metastases using selective arterial
chemoembolization has also been reported in nonrandomized
studies. In one study two of five patients with advanced MTC
and diarrhea had an objective response to chemoemboliza-
tion, and in a second study, all six patients with diarrhea
improved following chemoembolization (326,328).
& RECOMMENDATION 66
Patients with advancedMTC and diarrhea should be treated
initially with antimotility agents. Alternative therapies in-
clude somatostatin analogs and local therapies such as
surgery or chemoembolization. Grade C Recommendation
[W-2] Ectopic Cushing’s syndrome
MTC can occasionally secrete high levels of bioactive
hormones other than Ctn. The most common ectopic hor-
mones, CRH or ACTH, can cause Cushing’s syndrome. MTC
is reported to account for up to 1%–3% of all cases of ectopic
Cushing’s syndrome (361,362). Control of elevated cortisol
levels, and the associated clinical manifestations, may be
achieved by debulking of large hepatic metastases (surgery
or chemoembolization); by medical therapy using ketoco-
nazole, mifepristone, aminoglutethimide (where available),
metyrapone, or mitotane; or by bilateral adrenalectomy
(363). The development of Cushing’s syndrome in patients
with advanced MTC is associated with poor survival; how-
ever, because the syndrome can be severe and debilitating,
treatment should be considered even in the setting of widely
metastatic MTC. It is important to treat hypokalemia, hy-
pertension, diabetes, and gastritis in patients with ectopic
Cushing’s syndrome. It is of interest that there have been
three recent reports of reversal of Cushing’s syndrome fol-
lowing the administration of vandetanib to patients with ad-
vanced MTC, which may provide another therapeutic option
(364,365).
& RECOMMENDATION 67
Patients with metastatic MTC and Cushing’s syndrome
due to ectopic production of ACTH or CRH are often
markedly debilitated and should be treated despite their
poor prognosis. Treatment options include medical ther-
apy with ketoconazole, mifepristone, aminoglutethimide,
metyrapone, or mitotane. In cases refractory to medical
treatment bilateral adrenalectomy is an option. Grade C
Recommendation
EPILOG
The revised ATA Management Guidelines for Medullary
Thyroid Carcinoma were written to provide clinicians with
direction in the management of patients with sporadic and
hereditary MTC. Despite significant advances in the diag-
nosis and treatment of patients with MTC, much remains to
be done. In patients with advanced MTC there is a critical
need for more effective therapies. The TKIs vandetanib and
cabozantinib have increased PFS compared to placebo in
patients with advanced MTC; however, with time the MTC
becomes resistant to these drugs and the disease progresses.
Although new molecular targeted therapeutics will be eval-
uated in clinical trials, it is unlikely that a single compound
will be curative. Hopefully, preclinical studies of tumor cells
and animal models of MTC, and especially molecular anal-
ysis of tumor tissues collected from patients on TKI clinical
trials, will lead to an understanding of the mechanisms of
tumor resistance, and thereby the development of effective
combinatorial therapies.
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